Kurt Huber

Q: What Schools Are Affiliated With Kurt Huber

Kurt Huber is affiliated with the following schools: University of Vienna, Medical University of Graz, Aarhus University, Medical University of Vienna, Uppsala University, Columbia University

Kurt Huber's AcademicInfluence.com Rankings

Kurt Huber

Medical

#1689

World Rank

#2055

Historical Rank

Cardiology

#135

World Rank

#138

Historical Rank

medical Degrees

Kurt Huber

Philosophy

#5103

World Rank

#7828

Historical Rank

Logic

#2436

World Rank

#3426

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Kurt Huber's Degrees

PhD Cardiology University of Zurich

Why Is Kurt Huber Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Kurt Huber's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. (2012) (7528)
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation (2012) (4622)
Guidelines on myocardial revascularization. (2010) (2752)
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. (2008) (2081)
Guidelines on myocardial revascularization. (2010) (1272)
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial (2011) (1141)
2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). (2014) (983)
2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). (2014) (880)
Apixaban with antiplatelet therapy after acute coronary syndrome. (2011) (872)
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. (2012) (718)
[Guidelines on the management of stable angina pectoris: executive summary]. (2006) (705)
Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries (2009) (640)
Recommendations for the use of cardiac troponin measurement in acute cardiac care. (2010) (619)
PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock (2017) (614)
MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS PRESENTING WITH PERSISTENT ST-SEGMENT ELEVATION (ENDING) (2009) (590)
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (2014) (550)
Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease (2002) (550)
Ticagrelor with or without Aspirin in High-Risk Patients after PCI. (2019) (539)
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial (2009) (486)
How to use high-sensitivity cardiac troponins in acute cardiac care (2012) (484)
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. (2012) (481)
Bivalirudin started during emergency transport for primary PCI. (2013) (473)
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. (2013) (418)
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial (2017) (405)
Implementation of Guidelines Improves the Standard of Care: The Viennese Registry on Reperfusion Strategies in ST-Elevation Myocardial Infarction (Vienna STEMI Registry) (2006) (403)
Vitamin K antagonists in heart disease: Current status and perspectives (Section III) (2013) (385)
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial (2018) (378)
Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. (2011) (364)
Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care** and Thrombosis of the European Society of Cardiology. (2013) (349)
How to use high-sensitivity cardiac troponins in acute cardiac care. (2013) (345)
Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting (2009) (326)
Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. (2014) (326)
Abciximab in Patients With Acute ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading: A Randomized Double-Blind Trial (2009) (323)
Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. (2014) (293)
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. (2015) (288)
Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. (2012) (288)
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial (2011) (282)
Endurance training increases the number of endothelial progenitor cells in patients with cardiovascular risk and coronary artery disease. (2005) (267)
Prehospital ticagrelor in ST-segment elevation myocardial infarction. (2014) (266)
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. (2012) (265)
Parenteral anticoagulants in heart disease: Current status and perspectives (Section II) (2013) (251)
One‐Year Outcomes after PCI Strategies in Cardiogenic Shock (2018) (249)
ESC / ESA Guidelines on non-cardiac surgery : cardiovascular assessment and management (2014) (249)
Bleeding risk assessment and management in atrial fibrillation patients (2011) (247)
Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) a (2010) (242)
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. (2012) (231)
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention (2013) (228)
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study (2013) (222)
Antiplatelet agents for the treatment and prevention of atherothrombosis. (2011) (220)
Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. (2011) (216)
Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation (2013) (205)
Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study (2014) (202)
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). (2013) (196)
2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European (2018) (183)
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. (2015) (183)
Intracoronary KAI-9803 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction (2008) (182)
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. (2014) (179)
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. (2013) (177)
Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis (2012) (174)
Early glycoprotein IIb–IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis (2008) (172)
General mechanisms of coagulation and targets of anticoagulants (Section I) (2013) (172)
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER (2018) (171)
How is cardiac troponin released from injured myocardium? (2018) (170)
Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. (2009) (164)
Simvastatin Blunts Endotoxin-Induced Tissue Factor In Vivo (2005) (164)
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel (2014) (161)
Assessment of repolarization heterogeneity for prediction of mortality in cardiovascular disease: peak to the end of the T wave interval and nondipolar repolarization components. (2011) (152)
Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. (2006) (150)
Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF (2016) (149)
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial (2008) (146)
Serial Noninvasive In Vivo Positron Emission Tomographic Tracking of Percutaneously Intramyocardially Injected Autologous Porcine Mesenchymal Stem Cells Modified for Transgene Reporter Gene Expression (2008) (146)
Does Carotid Stent Cell Design Matter? (2008) (145)
Circadian Fluctuations of Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma of Patients with Unstable Coronary Artery Disease and Acute Myocardial Infarction (1988) (143)
Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta‐analysis (2010) (141)
[Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation]. (2009) (140)
Early glycoprotein IIb‐IIIa inhibitors in primary angioplasty‐abciximab long‐term results (EGYPT‐ALT) cooperation: individual patient’s data meta‐analysis (2011) (139)
C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. (2002) (139)
Interleukin-33 Induces Expression of Adhesion Molecules and Inflammatory Activation in Human Endothelial Cells and in Human Atherosclerotic Plaques (2011) (138)
APPRAISE 2. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome for the APPRAISE-2 Investigators* (2011) (136)
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials (2012) (136)
Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature (2013) (135)
Response variability to P2Y12 receptor inhibitors: expectations and reality. (2013) (128)
Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. (2015) (128)
Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. (2005) (128)
EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic (2020) (125)
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. (2009) (125)
HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins (2002) (122)
Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6 (2002) (122)
Thienopyridines in cardiovascular disease: Focus on Clopidogrel resistance (2007) (121)
Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis (2018) (121)
Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial (2012) (119)
Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. (2019) (111)
Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis (2016) (109)
Heme oxygenase-1 gene promoter polymorphism is associated with abdominal aortic aneurysm. (2002) (109)
Progression of Carotid Stenosis Detected by Duplex Ultrasonography Predicts Adverse Outcomes in Cardiovascular High-Risk Patients (2007) (107)
Prognostic value of apoptosis markers in advanced heart failure patients. (2008) (106)
Familial-combined hyperlipidaemia in very young myocardial infarction survivors (< or =40 years of age). (2009) (101)
Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. (2001) (99)
Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intra (2009) (98)
Quality indicators for acute myocardial infarction: A position paper of the Acute Cardiovascular Care Association (2017) (96)
Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. (2011) (95)
Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. (2004) (95)
Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. (2009) (93)
Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction* (2006) (92)
The association between C‐reactive protein on admission and mortality in patients with acute myocardial infarction (2000) (89)
Can a Commercial Diagnostic Ultrasound Device Accelerate Thrombolysis?: An In Vitro Skull Model (2004) (88)
Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: A document of the Acute Cardiovascular Care Association of the European Society of Cardiology (2020) (88)
D‐dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation – observations from the ARISTOTLE trial (2014) (88)
The complement component C5a is present in human coronary lesions in vivo and induces the expression of MMP‐1 and MMP‐9 in human macrophages in vitro (2011) (88)
Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial. (2016) (87)
Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial (2014) (86)
Endurance training reduces circulating inflammatory markers in persons at risk of coronary events: impact on plaque stabilization? (2006) (86)
Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial (2016) (86)
Plasminogen Activator Inhibitor Type-1 (Part One): Basic Mechanisms, Regulation, and Role for Thromboembolic Disease (2001) (86)
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. (2003) (86)
Complementary role of copeptin and high‐sensitivity troponin in predicting outcome in patients with stable chronic heart failure (2011) (84)
Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. (2019) (84)
2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA) (2014) (83)
Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. (2016) (83)
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. (2018) (83)
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI (2010) (82)
Cell therapy for human ischemic heart diseases: critical review and summary of the clinical experiences. (2014) (81)
A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with increased bilirubin and HDL levels but not with coronary artery disease (2003) (80)
A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention: The INNOVATE-PCI Trial (2012) (80)
Pigment epithelium-derived factor (PEDF) as a therapeutic target in cardiovascular disease (2009) (80)
A Decrease in Plasminogen Activator Inhibitor-1 Activity after Successful Percutaneous Transluminal Coronary Angioplasty Is Associated with a Significantly Reduced Risk for Coronary Restenosis (1992) (79)
Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Similarities and dissimilarities between North America and Europe (2011) (79)
Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. (1994) (79)
Interleukin-1 receptor antagonist genotype is associated with coronary atherosclerosis in patients with type 2 diabetes. (2002) (78)
Soluble ST2 and Interleukin-33 Levels in Coronary Artery Disease: Relation to Disease Activity and Adverse Outcome (2014) (78)
Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery (2014) (78)
High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. (2002) (78)
Euro Heart Survey 2009 Snapshot: regional variations in presentation and management of patients with AMI in 47 countries (2013) (77)
Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis (2010) (76)
Soluble selectins and the systemic inflammatory response syndrome after successful cardiopulmonary resuscitation (2000) (76)
Pre-hospital reperfusion therapy: a strategy to improve therapeutic outcome in patients with ST-elevation myocardial infarction. (2005) (76)
Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. (2010) (75)
Catecholamines potentiate LPS‐induced expression of MMP‐1 and MMP‐9 in human monocytes and in the human monocytic cell line U937: possible implications for peri‐ operative plaque instability (2004) (74)
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial (2017) (74)
Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. (2015) (74)
Differential in vivo activation of monocyte subsets during low-grade inflammation through experimental endotoxemia in humans (2016) (73)
ESC guidelines on management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. (2009) (73)
Profibrinolytic, Antithrombotic, and Antiinflammatory Effects of an Insulin-Sensitizing Strategy in Patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial (2011) (73)
Rapid rule out of acute myocardial infarction: novel biomarker-based strategies (2017) (71)
Antiplatelet Treatment for Prevention of Cerebrovascular Events in Patients With Vascular Diseases: A Systematic Review and Meta-Analysis (2014) (70)
What to do when you question cardiac troponin values (2018) (70)
How to use D-dimer in acute cardiovascular care (2017) (70)
Tissue factor is induced by interleukin-33 in human endothelial cells: a new link between coagulation and inflammation (2016) (70)
Risk Score for Peri-Interventional Complications of Carotid Artery Stenting (2006) (69)
Plasminogen Activator Inhibitor 1 Expression is Regulated by the Inflammatory Mediators Interleukin-1α, Tumor Necrosis Factor-α, Transforming Growth Factor-β and Oncostatin M in Human Cardiac Myocytes ☆ (2002) (68)
Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) (2021) (68)
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. (2022) (68)
The organization, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directions. (2014) (67)
Endurance training reduces circulating asymmetric dimethylarginine and myeloperoxidase levels in persons at risk of coronary events (2005) (67)
Usefulness of procalcitonin for diagnosing complicating sepsis in patients with cardiogenic shock (2003) (67)
A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. (2013) (67)
Ticagrelor With or Without Aspirin After Complex PCI (2020) (66)
Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (≤ 40 years of age) (2012) (66)
Rationale and design of POPular-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation. (2016) (65)
Inherited platelet glycoprotein polymorphisms and a risk for coronary heart disease in young central Europeans. (1998) (65)
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. (2020) (65)
Diagnosis and risk stratification of chest pain patients in the emergency department: focus on acute coronary syndromes. A position paper of the Acute Cardiovascular Care Association (2020) (65)
Increased prevalence of a polymorphism in the gene coding for human prothrombin in patients with coronary heart disease. (1997) (62)
Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies. (2005) (61)
Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro. (2006) (61)
Complex formation between urokinase and plasma protein C inhibitor in vitro and in vivo. (1989) (60)
Prospective Evaluation of Clinical Outcomes After Acute ST-Elevation Myocardial Infarction in Patients Who Are Ineligible for Reperfusion Therapy: Preliminary Results From the TETAMI Registry and Randomized Trial (2003) (58)
Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA) (2021) (57)
Opposite effects of CX3CR1 receptor polymorphisms V249I and T280M on the development of acute coronary syndrome (2005) (57)
Inflammation and cardiac outcome (2011) (56)
Mitochondrial DNA and Toll-Like Receptor-9 Are Associated With Mortality in Critically Ill Patients (2015) (56)
Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen. (1993) (56)
Oncostatin M-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves PI3K-, p38 MAPK-, Erk1/2- and STAT1/STAT3-dependent pathways and is attenuated by interferon-γ (2011) (55)
The role of platelets in athero-thrombotic events. (2012) (55)
Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease (2016) (55)
Contemporary use of glycoprotein IIb/IIIa inhibitors (2012) (54)
Polymorphic membrane protein (PMP) 20 and PMP 21 of Chlamydia pneumoniae induce proinflammatory mediators in human endothelial cells in vitro by activation of the nuclear factor-kappaB pathway. (2003) (54)
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. (2016) (54)
Plasminogen Activator Inhibitor-1 Levels in Patients with Chronic Angina Pectoris with or without Angiographic Evidence of Coronary Sclerosis (1990) (54)
Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis (2017) (54)
Routinely available biomarkers improve prediction of long-term mortality in stable coronary artery disease: the Vienna and Ludwigshafen Coronary Artery Disease (VILCAD) risk score. (2012) (54)
Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation. (2009) (53)
Pre-hospital treatment of STEMI patients. A scientific statement of the Working Group Acute Cardiac Care of the European Society of Cardiology (2011) (53)
2MHz ultrasound enhances t-PA-mediated thrombolysis: comparison of continuous versus pulsed ultrasound and standing versus travelling acoustic waves (2003) (53)
A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial). (2013) (53)
Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing (2015) (52)
Effect of Glycoprotein IIb/IIIa Antagonist Abciximab on Monocyte-Platelet Aggregates and Tissue Factor Expression (2003) (52)
New Aspects in Thrombotic Research: Complement Induced Switch in Mast Cells from a Profibrinolytic to a Prothrombotic Phenotype (2003) (51)
Ultrasound thrombolysis (2005) (51)
Clinical and experimental evidence of prostaglandin E1-induced angiogenesis in the myocardium of patients with ischemic heart disease. (2002) (50)
[European National Society cardiovascular journals. Background, rationale and mission statement of the "Editors' Club"]. (2008) (50)
Ultrasound affects distribution of plasminogen and tissuetype plasminogen activator in whole blood clots in vitro (2004) (50)
Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation (2010) (50)
How to use C-reactive protein in acute coronary care. (2013) (50)
Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. (2019) (49)
Gender-related outcome following percutaneous coronary intervention for ST-elevation myocardial infarction: data from the Austrian acute PCI registry. (2008) (49)
An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. (2020) (49)
Chlamydia pneumoniae in Carotid Artery Atherosclerosis: A Comparison of Its Presence in Atherosclerotic Plaque, Healthy Vessels, and Circulating Leukocytes From the Same Individuals (2002) (48)
The anti-angiogenic factor PEDF is present in the human heart and is regulated by anoxia in cardiac myocytes and fibroblasts (2009) (48)
Serum levels of ischemia-modified albumin in healthy volunteers after exercise-induced calf-muscle ischemia (2007) (48)
Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights from the AUGUSTUS Trial. (2019) (48)
Premature myocardial infarction is strongly associated with increased levels of remnant cholesterol. (2015) (47)
Ticagrelor with or without Aspirin in High-Risk Patients with Diabetes Mellitus undergoing Percutaneous Coronary Intervention. (2020) (47)
Hepatic synthesis and clearance of components of the fibrinolytic system in healthy volunteers and in patients with different stages of liver cirrhosis. (1991) (47)
Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease. (1998) (46)
How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors – is an algorithm the answer? (2015) (46)
Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort. (2007) (46)
Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF) (2019) (45)
Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. (2018) (45)
Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events (2011) (45)
Characterization of a specific anti-human urokinase antibody: development of a sensitive competition radioimmunoassay for urokinase antigen. (1984) (45)
Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9. (2010) (44)
Is low serum bilirubin an independent risk factor for coronary artery disease in men but not in women? (2003) (44)
Use of copeptin for rapid rule-out of acute myocardial infarction (2018) (44)
Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes. (2002) (43)
N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. (2004) (43)
In Human Macrophages the Complement Component C5a Induces the Expression of Oncostatin M via AP-1 Activation (2008) (43)
Pre-hospital management of patients with chest pain and/or dyspnoea of cardiac origin. A position paper of the Acute Cardiovascular Care Association (ACCA) of the ESC. (2020) (43)
Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease (2014) (43)
Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb–IIIa inhibitors: insights from the EGYPT cooperation (2010) (42)
Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial (2018) (42)
Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. (2013) (42)
Premature myocardial infarction is associated with low serum levels of Wnt-1. (2012) (42)
Network models for large cities: the European experience (2010) (42)
Monocyte chemoattractant protein (MCP‐1) is expressed in human cardiac cells and is differentially regulated by inflammatory mediators and hypoxia (2006) (42)
Non-conventional markers of atherosclerosis before and after gastric banding surgery. (2009) (42)
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). (2014) (41)
Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a. (2010) (41)
Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. (2015) (41)
In search for the Holy Grail: Suggestions for studies to define delta changes to diagnose or exclude acute myocardial infarction: a position paper from the study group on biomarkers of the Acute Cardiovascular Care Association (2014) (40)
An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion. (2005) (40)
Fractalkine is an independent predictor of mortality in patients with advanced heart failure (2012) (40)
Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-st-segment elevation myocardial infarction. (2004) (40)
The K121Q polymorphism in the plasma cell membrane glycoprotein 1 gene predisposes to early myocardial infarction (2002) (40)
B-type Natriuretic Peptide and Risk of Contrast-Induced Acute Kidney Injury in Acute ST-Segment–Elevation Myocardial Infarction: A Substudy from the HORIZONS-AMI Trial (2012) (39)
Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial (2018) (39)
Antithrombotic therapy for acute coronary syndrome: Past, present and future (2017) (39)
Ticagrelor With Aspirin or Alone After Complex PCI: The TWILIGHT-COMPLEX Analysis. (2020) (39)
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? (2014) (39)
Early assessment of outcome in cardiogenic shock: Relevance of plasma N-terminal pro-B-type natriuretic peptide and interleukin-6 levels* (2009) (39)
Glycoprotein 130 ligand oncostatin-M induces expression of vascular endothelial growth factor in human adult cardiac myocytes. (2003) (38)
Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force (2015) (38)
Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure (2011) (38)
Enhancing the efficacy of delivering reperfusion therapy: a European and North American experience with ST-segment elevation myocardial infarction networks. (2013) (38)
Thrombolytic agents--an overview. (1996) (38)
Pharmacokinetic basis of the antiplatelet action of prasugrel (2012) (37)
Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas (1987) (37)
INTERLEUKIN-6 AND C-REACTIVE PROTEIN AND RISK FOR DEATH AND CARDIOVASCULAR EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION (2011) (37)
Plasma concentrations of von Willebrand factor and intracellular adhesion molecule-1 for prediction of outcome after successful cardiopulmonary resuscitation (2003) (37)
Neutrophil Extracellular Trap Degradation by Differently Polarized Macrophage Subsets (2020) (36)
Urinary Excretion of Apo(a) Fragments: Role in Apo(a) Catabolism (1996) (36)
[2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment andmanagement]. (2014) (36)
Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphism in coronary disease and malignant ventricular arrhythmias. (1999) (36)
2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group. (2021) (36)
Association of Small Dense LDL Serum Levels and Circulating Monocyte Subsets in Stable Coronary Artery Disease (2015) (36)
Prognostic Value of Undetectable hs Troponin T in Suspected Acute Coronary Syndrome. (2016) (35)
The Role of Gender and Other Factors as Predictors of Not Receiving Reperfusion Therapy and of Outcome in ST-Segment Elevation Myocardial Infarction (2005) (35)
Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial. (2019) (35)
New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes (2012) (35)
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial. (2020) (35)
Comparison of HbA1c and oral glucose tolerance test for diagnosis of diabetes in patients with coronary artery disease (2012) (35)
PAI-I 4G/5G polymorphism and sudden cardiac death in patients with coronary artery disease. (2001) (35)
A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI (2016) (35)
Differential effect of ischaemic preconditioning on mobilisation and recruitment of haematopoietic and mesenchymal stem cells in porcine myocardial ischaemia-reperfusion (2010) (35)
Editor’s Choice-Rule-in of acute myocardial infarction: Focus on troponin (2017) (34)
NGAL and MMP-9/NGAL as biomarkers of plaque vulnerability and targets of statins in patients with carotid atherosclerosis (2017) (34)
Stress-induced cardiomyopathy (Tako-Tsubo syndrome) in Austria (2013) (34)
Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care? (2017) (34)
Clinical predictors of patient related delay in the VIENNA ST-elevation myocardial infarction network and impact on long-term mortality (2017) (34)
Platelet function variability and non-genetic causes (2011) (33)
MicroRNAs as circulating biomarkers in acute coronary syndromes: A review. (2016) (33)
Monocyte subset distribution in patients with stable atherosclerosis and elevated levels of lipoprotein(a) (2015) (33)
Circadian Fluctuations in Plasma Levels of Tissue Plasminogen Activator Antigen and Plasminogen Activator Inhibitor Activity (1989) (33)
Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. (2010) (33)
Platelet function testing in acute cardiac care – is there a role for prediction or prevention of stent thrombosis and bleeding? (2014) (33)
Homocysteine plasma levels in young patients with coronary artery disease. Relation to history of acute myocardial infarction and anatomical extent of disease. (2001) (33)
Cardiovascular biomarkers in patients with COVID-19 (2021) (32)
Evaluation of Fibrinolytic Capacity in Plasma during Thrombolytic Therapy with Single (scu-PA) or Two-chain Urokinase Type Plasminogen Activator (tcu-PA) by a Combined Assay System for Urokinase Type Plasminogen Activator Antigen and Function (1989) (32)
CYP2C9*2 and CYP2C9*3 alleles confer a lower risk for myocardial infarction. (2004) (32)
Clinical restenosis after coronary stent implantation is associated with the heme oxygenase-1 gene promoter polymorphism and the heme oxygenase-1 +99G/C variant. (2005) (32)
A European perspective on improving acute systems of care in STEMI: we know what to do, but how can we do it? (2008) (32)
IL-33 stimulates the release of procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets (2017) (32)
Butyrylcholinesterase activity predicts long-term survival in patients with coronary artery disease. (2012) (31)
Plasma osmolality predicts clinical outcome in patients with acute coronary syndrome undergoing percutaneous coronary intervention (2014) (31)
Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: analysis from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial. (2011) (31)
Diabetes as a coronary artery disease risk equivalent: before a change of paradigm? (2010) (31)
Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation (2013) (31)
Platelet Turnover Predicts Outcome after Coronary Intervention (2017) (31)
Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. (2018) (31)
Oncostatin M and IL-6 induce u-PA and VEGF in prostate cancer cells and correlate in vivo. (2011) (30)
The effect of p22-PHOX (CYBA) polymorphisms on premature coronary artery disease (≤ 40 years of age) (2010) (30)
Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H²⁴ Analysis. (2015) (30)
An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis (2014) (29)
Urokinase Antigen in Plasma of Patients with Liver Cirrhosis and Hepatoma (1985) (29)
Predictive value of plasma plasminogen activator inhibitor‐1 for coronary restenosis: dependence on stent implantation and antithrombotic medication (2005) (29)
Impairment of the Plasmin Activation System in Primary Pulmonary Hypertension: Evidence for Gender Differences (2001) (29)
Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices. (2021) (29)
Genetic variability in response to clopidogrel therapy and its clinical implications (2011) (29)
Prostaglandin E1 induces vascular endothelial growth factor-1 in human adult cardiac myocytes but not in human adult cardiac fibroblasts via a cAMP-dependent mechanism. (2004) (29)
Gender differences in short- and long-term mortality in the Vienna STEMI registry. (2017) (29)
Predictors of survival in unselected patients with acute myocardial infarction requiring continuous catecholamine support. (2002) (28)
Frequency and Impact of Bleeding on Outcome in Patients With Cardiogenic Shock. (2020) (28)
Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome (2019) (28)
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. (2021) (28)
Routine stent implantation vs. percutaneous transluminal angioplasty in femoropopliteal artery disease: a meta-analysis of randomized controlled trials (2009) (28)
The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI 3-kinase and ERK1/2-dependent pathways. (2007) (28)
Soluble galectin‐3 is associated with premature myocardial infarction (2016) (28)
Markers of bone metabolism in premature myocardial infarction (≤ 40 years of age). (2011) (28)
Type 2 diabetes and the progression of visualized atherosclerosis to clinical cardiovascular events. (2013) (27)
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes (2014) (27)
Fresh from the pipeline. Ticagrelor. (2011) (27)
Determination of plasma urokinase-type plasminogen activator antigen in patients with primary liver cancer: characterization as tumor-associated antigen and comparison with alpha-fetoprotein. (1992) (27)
The honey man--second degree heart block after honey intoxication. (2010) (27)
Bleeding and ischemic outcomes in patients treated with dual or triple antithrombotic therapy - systematic review and meta-analysis. (2019) (27)
High-degree atrioventricular block in patients with preexisting bundle branch block or bundle branch block occurring during transcatheter aortic valve implantation. (2014) (27)
The E-selectin S128R polymorphism is not a risk factor for coronary artery disease in patients with diabetes mellitus type 2. (2003) (27)
Impact of TIMI 3 patency before primary percutaneous coronary intervention for ST-elevation myocardial infarction on clinical outcome: results from the ASSENT-4 PCI study (2012) (26)
Human cardiac fibroblasts express B-type natriuretic peptide: fluvastatin ameliorates its up-regulation by interleukin-1α, tumour necrosis factor-α and transforming growth factor-β (2009) (26)
Efficacy and Safety of Clopidogrel 600 mg Administered Pre-Hospitally to Improve Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction (CIPAMI): Study Rationale and Design (2006) (26)
Fractalkine receptor polymorphisms V249I and T280M as genetic risk factors for restenosis (2005) (25)
Genetic variability in response to clopidogrel therapy: clinical implications. (2010) (25)
Levosimendan exerts anti-inflammatory effects on cardiac myocytes and endothelial cells in vitro (2014) (25)
Vascular effects of glycoprotein130 ligands--part I: pathophysiological role. (2012) (25)
One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial (2010) (25)
Functional testing methods for the antiplatelet effects of aspirin. (2011) (25)
Long-term mortality of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation for acute and stable coronary artery disease. (2015) (25)
ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation (2013) (24)
Circulating microRNAs identify patients at increased risk of in-stent restenosis after peripheral angioplasty with stent implantation. (2018) (24)
Sex-Specific Management in Patients With Acute Myocardial Infarction and Cardiogenic Shock (2020) (24)
High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. (2019) (24)
Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. (2018) (24)
Complement Component C5a Predicts Restenosis after Superficial Femoral Artery Balloon Angioplasty (2007) (24)
Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation. (2013) (23)
Predictors of response to renal denervation for resistant arterial hypertension: a single center experience (2016) (23)
Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged (2015) (23)
Sex-related differences in baseline characteristics, management and outcome in patients with acute coronary syndrome without ST-segment elevation (2016) (23)
Plasminogen Activator Inhibitor Type-1 (Part Two): Role for Failure of Thrombolytic Therapy. PAI-1 Resistance as a Potential Benefit for New Fibrinolytic Agents (2001) (23)
Usefulness of pre-operative copeptin concentrations to predict post-operative outcome after major vascular surgery. (2011) (23)
Copeptin for the early rule-out of non-ST-elevation myocardial infarction. (2016) (23)
Plasminogen activator inhibitor type 1 and outcome after successful cardiopulmonary resuscitation (2001) (23)
The ACE-inhibitor lisinopril affects plasma insulin levels but not fibrinolytic parameters. (1996) (23)
New cut-off values of cardiac markers for risk stratification of angina pectoris. (2004) (23)
Interleukin-33 stimulates GM-CSF and M-CSF production by human endothelial cells (2016) (22)
The TETAMI Trial: The Safety and Efficacy of Subcutaneous Enoxaparin versus Intravenous Unfractionated Heparin and of Tirofiban versus Placebo in the Treatment of Acute Myocardial Infarction for Patients Not Thrombolyzed: Methods and Design (2000) (22)
Plasmin Activation System in Restenosis: Role in Pathogenesis and Clinical Prediction? (1999) (22)
MicroRNAs as Regulators and Biomarkers of Platelet Function and Activity in Coronary Artery Disease (2019) (22)
Fetuin-A Characteristics during and after Pregnancy: Result from a Case Control Pilot Study (2012) (22)
Impact of age on short- and long-term mortality of patients with ST-elevation myocardial infarction in the VIENNA STEMI network (2018) (22)
PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. (2020) (22)
The impact of place of enrollment and delay to reperfusion on 90-day post-infarction mortality in the ASSENT-4 PCI trial: assessment of the safety and efficacy of a new treatment strategy with percutaneous coronary intervention. (2009) (22)
Determinants of growth differentiation factor 15 in patients with stable and acute coronary artery disease. A prospective observational study (2016) (22)
How can we optimize the processes of care for acute coronary syndromes to improve outcomes? (2014) (21)
Heparin induced increase of t-PA antigen plasma levels in patients with unstable angina: no evidence for clinical benefit of heparinization during the initial phase of treatment. (1989) (21)
Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine (2018) (21)
Thrombolytic agents - An updated overview (1998) (21)
PAI-1 (Plasminogen Activator Inhibitor-1) Expression Renders Alternatively Activated Human Macrophages Proteolytically Quiescent (2017) (21)
Impaired antioxidant HDL function is associated with premature myocardial infarction (2015) (21)
Predictive value of low interleukin‐33 in critically ill patients (2017) (21)
Primary percutaneous intervention of ST-elevation myocardial infarction in Austria: Results from the Austrian acute PCI registry 2005–2007 (2010) (21)
Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide. (2005) (21)
The management of patients on oral anticoagulation undergoing coronary stent implantation: a survey among interventional cardiologists from eight European countries. (2012) (21)
Differential expression of Plg-RKT and its effects on migration of proinflammatory monocyte and macrophage subsets. (2019) (20)
New anticoagulant agents in acute coronary syndromes (2010) (20)
Awareness, treatment, and control of hypertension in Austria: a multicentre cross-sectional study (2016) (20)
Vasodilator-stimulated phosphoprotein-phosphorylation assay in patients on clopidogrel: Does standardisation matter? (2012) (20)
Antiplatelet therapy and coronary stents in perioperative medicine--the two sides of the coin. (2008) (20)
Covid-19: implications for prehospital, emergency and hospital care in patients with acute coronary syndromes (2020) (20)
Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes trial. (2015) (20)
The estrogen metabolite 17β-dihydroequilenin counteracts interleukin-1α induced expression of inflammatory mediators in human endothelial cells in vitro via NF-κB pathway (2005) (20)
Variability of on-treatment platelet reactivity in patients on clopidogrel (2014) (20)
The role of ST-segment elevation in lead aVR in the risk assessment of patients with acute pulmonary embolism (2012) (20)
Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity troponin T (2020) (20)
Protective effect of ischaemic preconditioning on ischaemia/reper-fusion-induced microvascular obstruction determined by online measurements of coronary pressure and blood flow in pigs (2009) (20)
New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint. (2015) (20)
Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. (2015) (20)
123I-MIBG heart-to-mediastinum ratio is influenced by high-energy photon penetration of collimator septa from liver and lung activity (2015) (19)
Lipid profile and long‐term outcome in premature myocardial infarction (2018) (19)
Long-term outcome after drug-eluting stent implantation in comparison with bare metal stents: a single centre experience (2011) (19)
Impact of advanced age on myocardial perfusion, distal embolization, and mortality patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb–IIIa inhibitors (2013) (19)
The role of fibrinolysis in the era of primary percutaneous coronary intervention (2010) (19)
Influence of high-dose highly efficient statins on short-term mortality in patients undergoing percutaneous coronary intervention with stenting for acute coronary syndromes. (2014) (19)
Tissue-type plasminogen activator and Type-1 plasminogen activator inhibitor in patients with coronary artery disease — Relations to clinical variables and cardiovascular risk factors (1995) (19)
Platelet glycoprotein Ia gene dimorphism alpha2-807 in malignant arrhythmia in coronary artery disease. (2000) (19)
Peri-operative management of antiplatelet therapy in patients with coronary artery disease (2011) (19)
Impact of transfer for primary percutaneous coronary intervention on survival and clinical outcomes (from the HORIZONS-AMI Trial). (2010) (19)
Rationale and Design of the ‘F.I.R.E.’ Study (2006) (18)
Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel. (2015) (18)
Circulating B-type natriuretic peptides in patients with acute coronary syndromes (2005) (18)
Liver-specific microRNA-122 as prognostic biomarker in patients with chronic systolic heart failure. (2019) (18)
Urokinase plasminogen activator protects cardiac myocytes from oxidative damage and apoptosis via hOGG1 induction (2017) (18)
Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial (2017) (18)
Comparison of effects of dalteparin and enoxaparin on hemostatic parameters and von Willebrand factor in patients with unstable angina pectoris or non--ST- segment elevation acute myocardial infarction. (2002) (18)
Monocyte subset distribution is associated with mortality in critically ill patients (2016) (18)
Platelet-monocyte cross talk and tissue factor expression in stable angina vs. unstable angina/non ST-elevation myocardial infarction (2011) (18)
Relationship Between Arterial Access and Outcomes in ST‐Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study (2016) (18)
Adipose tissue expression of interleukin-18 mRNA is elevated in subjects with metabolic syndrome and independently associated with fasting glucose (2011) (18)
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. (2021) (18)
Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation (2009) (18)
Multicentre cross-sectional observational registry to monitor the safety of early discharge after rule-out of acute myocardial infarction by copeptin and troponin: the Pro-Core registry (2019) (18)
Platelet activation and high tissue factor level predict acute stent thrombosis in pig coronary arteries: Prothrombogenic response of drug-eluting or bare stent implantation within the first 24 hours (2006) (18)
Fibrinolytic Balance of the Arterial Wall: Pulmonary Artery Displays Increased Fibrinolytic Potential Compared with Aorta (2003) (18)
Variations on classification of main types of myocardial infarction: a systematic review and outcome meta-analysis (2018) (17)
Association between advanced Killip class at presentation and impaired myocardial perfusion among patients with ST-segment elevation myocardial infarction treated with primary angioplasty and adjunctive glycoprotein IIb-IIIa inhibitors. (2009) (17)
The role of European national journals in education (2009) (17)
Predictive value of plasma Nt-proBNP and body mass index for recurrence of atrial fibrillation after cardioversion. (2011) (17)
Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial. (2020) (17)
Antithrombotic therapy in atrial fibrillation and stent implantation: treatment or threats by the use of triple or dual antithrombotic therapy (2013) (17)
Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus (2010) (17)
Prediction of cardiogenic shock using plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone concentrations in ST elevation myocardial infarction: An analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial (2010) (17)
Elevated risk of myocardial infarction in very young immigrants from former Yugoslavia (2009) (17)
Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation (2018) (17)
Design and methods of European Ambulance Acute Coronary Syndrome Angiography Trial (EUROMAX): an international randomized open-label ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment-elevation myocardial infarction transferred for primary percut (2013) (17)
Levels of von Willebrand factor and ADAMTS13 determine clinical outcome after cardioversion for atrial fibrillation (2010) (17)
Electrocardiogram changes and wall motion abnormalities in the acute phase of Tako-Tsubo syndrome (2016) (17)
Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. (2021) (16)
Predictive Value of PAI-1 Plasma Activity and Thallium Perfusion Imaging for Restenosis after Percutaneous Transluminal Angioplasty in Clinically Asymptomatic Patients (1999) (16)
ESC Study Group on Cardiac Biomarkers of the Association for Acute CardioVascular Care: A fond farewell at the retirement of CKMB. (2021) (16)
Biomarkers in acute coronary artery disease (2012) (16)
Plasminogen activators and plasminogen activator inhibitor in malignant and non‐malignant ascitic fluid (1988) (16)
Premature compared with late onset of coronary artery disease: young patients show a severe defect in fibrinolytic response to venous occlusion (2007) (16)
Impact of time from symptom onset to drug administration on outcome in patients undergoing glycoprotein IIb-IIIa facilitated primary angioplasty (from the EGYPT cooperation). (2015) (16)
Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome (2017) (16)
Implantation of paclitaxel-eluting stent impairs the vascular compliance of arteries in porcine coronary stenting model. (2009) (16)
Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial (2019) (16)
Effect of Antihypertensive Treatment with Doxazosin on Insulin Sensitivity and Fibrinolytic Parameters (1998) (16)
An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents. (2014) (16)
Influence of updated guidelines on short- and long-term mortality in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). (2012) (16)
Interleukin-1 gene cluster variants and abdominal aortic aneurysms (2005) (15)
Prognostic Impact of Soluble P-Selectin on Long-Term Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention (2018) (15)
Alternative activation of human macrophages enhances tissue factor expression and production of extracellular vesicles (2020) (15)
Impact of platelet turnover on long‐term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention (2019) (15)
Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points (2010) (15)
Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas. (1987) (15)
ApPropriateness of myocaRdial RevascularizatiOn assessed by the SYNTAX score II in a coUntry without cardiac Surgery faciliTies; PROUST study. (2017) (15)
A Validated Risk Score to Predict Outcomes after Carotid Stenting (2012) (15)
Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes (2013) (15)
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. (2021) (15)
Assessment of left ventricular function: comparison between radionuclide angiography and semiquantitative two-dimensional echocardiographic analysis (1996) (15)
Circulating t-PA antigen predicts major adverse coronary events in patients with stable coronary artery disease – a 13-year follow-up (2003) (15)
NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cutoffs Across Body Mass Index Categories. (2021) (15)
Intestinal Fatty Acid Binding Protein is Associated With Mortality in Patients With Acute Heart Failure or Cardiogenic Shock (2019) (14)
Association of metabolic syndrome and its individual components with outcomes among patients with high-risk non-ST-segment elevation acute coronary syndromes. (2014) (14)
Elevated baseline hs-cTnT levels predict exercise-induced myocardial ischemia in patients with peripheral arterial disease. (2012) (14)
Cardiac Arrest in the COVID-19 Era (2020) (14)
Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial. (2017) (14)
Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes. (2020) (14)
Impact of On-Site Cardiac Surgery on Clinical Outcomes After Transfemoral Transcatheter Aortic Valve Replacement. (2018) (14)
Inflammation and cardiovascular diseases: lessons that can be learned for the patient with cardiogenic shock in the intensive care unit (2004) (14)
Homocysteine Improves Risk Stratification in Patients Undergoing Endarterectomy for Asymptomatic Internal Carotid Artery Stenosis (2013) (14)
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY) (2019) (14)
Course of platelet miRNAs after cessation of P2Y12 antagonists (2019) (14)
Prognostic value of pigment epithelium-derived factor in patients with advanced heart failure. (2010) (14)
The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator. (1993) (14)
Long-term outcome and risk assessment in premature acute myocardial infarction: A 10-year follow-up study. (2017) (13)
EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. (2020) (13)
Mild hyperhomocysteinemia is associated with a decreased fibrinolytic activity in patients after ST-elevation myocardial infarction. (2007) (13)
Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial). (2019) (13)
Impact of distal embolization on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb–IIIa inhibitors: insights from the EGYPT cooperation (2010) (13)
The pre-hospital fibrinolysis experience in Europe and North America and implications for wider dissemination. (2011) (13)
Is increased platelet turnover responsible for low responsiveness to different thienopyridienes? A case report of recurrent stent thromboses (2011) (13)
Copeptin Predicts Mortality in Critically Ill Patients (2017) (13)
Effects of pretreatment with clopidogrel on platelet and coagulation activation in patients undergoing elective coronary stenting. (2003) (13)
Impact of hypertension on distal embolization, myocardial perfusion, and mortality in patients with ST segment elevation myocardial infarction undergoing primary angioplasty. (2013) (13)
Prognostic relevance of ischemia-modified albumin and NT-proBNP in patients with peripheral arterial occlusive disease. (2015) (13)
Protease‐activated receptor‐mediated platelet aggregation in acute coronary syndrome patients on potent P2Y12 inhibitors (2019) (13)
Remote ischaemic conditioning for myocardial infarction or elective PCI: systematic review and meta-analyses of randomised trials (2018) (13)
LEVELS OF PLASMINOGEN ACTIVATOR INHIBITOR IN PATIENTS WITH ANGINA PECTORIS (1987) (12)
Matrix Metalloproteinase-2 Impairs Homing of Intracoronary Delivered Mesenchymal Stem Cells in a Porcine Reperfused Myocardial Infarction: Comparison With Intramyocardial Cell Delivery (2018) (12)
Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre‐Specified Analysis of the GLOBAL LEADERS Trial (2021) (12)
The cardiac arrest centre for the treatment of sudden cardiac arrest due to presumed cardiac cause: aims, function, and structure: position paper of the ACVC association of the ESC, EAPCI, EHRA, ERC, EUSEM, and ESICM. (2020) (12)
Drug-eluting introducer sheath prevents local peripheral complications: pre-clinical evaluation of nitric oxide-coated sheath. (2011) (12)
Contrast induced acute kidney injury in acute coronary syndrome patients: A single centre experience (2016) (12)
Effects of Nicorandil on Inflammation, Apoptosis and Atherosclerotic Plaque Progression (2021) (12)
Glycoprotein 130 polymorphism predicts soluble glycoprotein 130 levels. (2014) (12)
Changes in Circulating Extracellular Vesicles in Patients with ST-Elevation Myocardial Infarction and Potential Effects of Remote Ischemic Conditioning—A Randomized Controlled Trial (2020) (12)
Antiplatelet drug induced isolated profound thrombocytopenia in interventional cardiology: a review based on individual case reports (2007) (12)
Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction? (2015) (12)
Time course of prothrombotic and proinflammatory substance release after intracoronary stent implantation (2008) (12)
Monocyte subsets in myocardial infarction: A review. (2017) (12)
Abstract 3007: Glycoprotein IIb/IIIa Inhibitors before Primary Percutaneous Coronary Intervention of ST-Elevation Myocardial Infarction Improve Perfusion and Outcomes: Insights from APEX-AMI (2007) (12)
Low high‐density lipoprotein cholesterol predicts cardiovascular events after carotid stenting: a long‐term survey (2007) (12)
Idiopathic Eosinophilic Endomyocarditis in the Absence of Peripheral Eosinophilia (2002) (11)
One-year mortality in patients with acute ST-elevation myocardial infarction in the Vienna STEMI registry (2015) (11)
Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome. (2017) (11)
The role of European national journals in education. (2010) (11)
Influence of Cardiac Output on Peak t-PA Plasma Levels in Patients Receiving Thrombolytic Therapy with Recombinant Tissue-Type Plasminogen Activator – Correlation with Patency Rate (1993) (11)
Bivalirudin in percutaneous coronary intervention: the EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry. (2014) (11)
Predictors of transportation delay in patients with suspected ST-elevation-myocardial infarction in the VIENNA-STEMI network (2019) (11)
Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized Acute myocardial infarction Treated with primary angioplasty and intravenous enoxaparin Or unfractionated h (2015) (10)
Issues in early risk stratification for UA/NSTEMI (2001) (10)
New anticoagulants for the prevention of stroke in atrial fibrillation (2012) (10)
Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry (2017) (10)
Prediction of clinical outcome in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) using the TIMI risk score extended by N-terminal pro-brain natriuretic peptide levels (2007) (10)
BNP and NT-proBNP in patients with acute myocardial infarction complicated by cardiogenic shock: results from the IABP Shock trial (2010) (10)
Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data (2021) (10)
Acute coronary syndromes and their pathophysiological basis (1997) (10)
The association of P2Y12 inhibitors with pro-coagulatory extracellular vesicles and microRNAs in stable coronary artery disease (2020) (10)
Efficacy and Safety of Apixaban Compared with Warfarin at Different Levels of Predicted INR Control for Stroke Prevention in Atrial Fibrillation (2013) (10)
Impact of time-to-treatment on myocardial perfusion after primary percutaneous coronary intervention with Gp IIb–IIIa inhibitors (2013) (10)
Soluble selectins in the pulmonary and systemic circulation in acute cardiogenic and non-cardiogenic pulmonary failure (2001) (10)
Anaesthesia in patients with drug-eluting stents (2008) (10)
Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial (2019) (10)
Primary PTCA versus thrombolysis with tPA in acute myocardial infarction: a formal cost-effectiveness analysis. (1999) (10)
Epicardial adipose tissue and cardiovascular outcome in patients with acute coronary syndrome undergoing percutaneous coronary intervention (2017) (10)
Vascular effects of glycoprotein130 ligands--part II: biomarkers and therapeutic targets. (2012) (10)
Impella in cardiogenic shock following acute myocardial infarction: a systematic review and meta-analysis (2020) (10)
Prognostic Impact of Atrial Fibrillation in Acute Myocardial Infarction and Cardiogenic Shock. (2019) (10)
Prognostic impact of familial hypercholesterolemia on long-term outcomes in patients undergoing percutaneous coronary intervention. (2019) (10)
Authorship: from credit to accountability. Reflections from the Editors’ Network (2019) (10)
The ISTH DIC score predicts outcome in non-septic patients admitted to a cardiovascular intensive care unit. (2020) (9)
Atorvastatin reduces thrombin generation after percutaneous coronary intervention independent of soluble tissue factor. (2005) (9)
Infection-associated biomarkers of inflammation in atherosclerosis. (2015) (9)
Impact of time of admission on short- and long-term mortality in the Vienna STEMI registry. (2017) (9)
Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. (2017) (9)
Platelets, inflammation and anti-inflammatory drugs in ACS and CAD (2015) (9)
Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS. (2017) (9)
G-CSF Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease (2015) (9)
Direct cardiovascular complications and indirect collateral damage during the COVID-19 pandemic (2021) (9)
Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial (2019) (9)
Impact of multivessel disease on myocardial perfusion and survival among patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitors. (2013) (9)
Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. (2020) (9)
The estrogen metabolite 17beta-dihydroequilenin counteracts interleukin-1alpha induced expression of inflammatory mediators in human endothelial cells in vitro via NF-kappaB pathway. (2006) (9)
Activated protein C levels and outcome in patients with cardiogenic shock complicating acute myocardial infarction (2017) (9)
Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY. (2021) (9)
The Austrian transcatheter aortic valve implantation (TAVI) Registry--3 years' data. (2014) (9)
Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices. (2021) (9)
Systematic screening for cardiovascular risk at pharmacies (2016) (9)
[Manual compression versus mechanical compression device (FemoStop) after diagnostic coronary angiography with/without intervention]. (2002) (8)
Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review (2022) (8)
Antiplatelet function variability in clopidogrel‐treated patients: need for new antiplatelet agents (2012) (8)
Ratio of Apolipoprotein A-II/B Improves Risk Prediction of Postoperative Survival After Carotid Endarterectomy (2015) (8)
Instant rule-out of suspected non-ST-segment elevation myocardial infarction using high-sensitivity cardiac troponin T with Copeptin versus a single low high-sensitivity cardiac troponin T: findings from a large pooled individual data analysis on 10,329 patients (2020) (8)
[Coronary stents, dual antiplatelet therapy and peri-operative problems]. (2007) (8)
Impact of preprocedural TIMI flow on clinical outcome in low‐risk patients with ST‐elevation myocardial infarction: Results from the ATLANTIC study (2020) (8)
Diurnal Variability of On-Treatment Platelet Reactivity in Clopidogrel versus Prasugrel Treated Acute Coronary Syndrome Patients: A Pre-Specified TROPICAL-ACS Sub-Study (2018) (8)
Oral antiplatelet therapy in acute coronary syndromes: update 2012 (2012) (8)
Elevated homocysteine serum level is associated with low enrichment of homocysteine in coronary arteries of patients with coronary artery disease. (2002) (8)
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. (2021) (8)
Increased platelet reactivity in dyslipidemic patients with coronary artery disease on dual anti-platelet therapy (2018) (8)
Duration of ischemia and treatment effects of pre‐ versus in‐hospital ticagrelor in patients with ST‐segment elevation myocardial infarction: Insights from the ATLANTIC study (2018) (8)
Platelet inhibition: new agents, new strategies, new trials (1998) (8)
Prognostic Impact of Active Mechanical Circulatory Support in Cardiogenic Shock Complicating Acute Myocardial Infarction, Results from the Culprit-Shock Trial (2020) (8)
Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different mates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries. (2021) (8)
[Conflict of interest policies and disclosure requirements among European Society of Cardiology national cardiovascular journals]. (2012) (8)
Statin treatment reduces matrix degradation capacity of proinflammatory polarized macrophages. (2018) (8)
Translational platelet research in patients with coronary artery disease: What are the major knowledge gaps? (2012) (8)
Influence of electrical stimulation therapy on permanent pacemaker function (2019) (8)
Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. (2011) (8)
Association between the efficacy of dual antiplatelet therapy and the development of in-stent neointimal hyperplasia in porcine coronary arteries (2008) (8)
Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention (2017) (8)
Impact of preprocedural TIMI flow on myocardial perfusion, distal embolization and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors. (2012) (7)
Genes expressed in coronary thrombi are associated with ischemic time in patients with acute myocardial infarction. (2015) (7)
Thrombogenicity and Antithrombotic Strategies in Structural Heart Interventions and Nonaortic Cardiac Device Therapy—Current Evidence and Practice (2019) (7)
Anti-thrombotic and pro-fibrinolytic effects of levosimendan in human endothelial cells in vitro. (2017) (7)
Revascularization of myocardial scar tissue following prostaglandin E1-therapy in patients with ischemic heart disease. (2003) (7)
Rationale and design of the 'F.I.R.E.' study. A multicenter, double-blind, randomized, placebo-controlled study to measure the effect of FX06 (a fibrin-derived peptide Bbeta(15-42)) on ischemia-reperfusion injury in patients with acute myocardial infarction undergoing primary percutaneous coronary i (2007) (7)
Interruption of non-vitamin K antagonist anticoagulants in patients undergoing planned invasive procedures: how long is long enough? (2017) (7)
Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper. (2022) (7)
Safety and efficacy of adjuvant glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention performed from the radial approach for acute ST segment elevation myocardial infarction. (2013) (7)
Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update. (2008) (7)
[Prasugrel, a new thienopyridine]. (2007) (7)
Thrombolytic therapy in acute myocardial infarction--update 1996. (1996) (7)
Restenosis following percutaneous revascularization--the potential role of thrombin and the thrombin receptor. (1996) (7)
High soluble Fas and soluble Fas Ligand serum levels before stent implantation are protective against restenosis (2011) (7)
Pharmacological inhibition of fatty acid oxidation reduces atherosclerosis progression by suppression of macrophage NLRP3 inflammasome activation. (2021) (7)
Copeptin combined with either non-high sensitivity or high sensitivity cardiac troponin for instant rule-out of suspected non-ST segment elevation myocardial infarction (2020) (7)
EFFICACY AND SAFETY OF APIXABAN COMPARED WITH WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN PATIENTS TAKING CONCOMITANT ASPIRIN (2012) (7)
Rationale and design of the MULTISTARS AMI Trial: A randomized comparison of immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease. (2020) (7)
High on-treatment platelet reactivity - why should we be concerned? (2013) (7)
Usefulness of Elevated Levels of Growth Differentiation Factor-15 to Classify Patients With Acute Coronary Syndrome Having Percutaneous Coronary Intervention Who Would Benefit from High-Dose Statin Therapy. (2017) (6)
The Decanucleotide Polymorphism in the Factor VII Promoter Predicts Factor VII Plasma Levels but not the Risk of Acute Coronary Syndromes (2000) (6)
Is P2Y12 inhibitor therapy associated with an increased risk of cancer? (2019) (6)
Dabigatran: patient management in specific clinical settings (2014) (6)
Non-bacterial thrombotic endocarditis in the context of pulmonary adenocarcinoma: a case report (2020) (6)
Twenty-four-hour time dependency of clopidogrel effects in patients with acute coronary syndromes: The CiCAD-Study (2018) (6)
Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction (2016) (6)
Restoration of coronary blood flow by single bolus injection of the gpiib/iiia receptor antagonist c7e3 fab in a patient with acute myocardial infarction of recent onset (1998) (6)
Evaluation of Myocardial Gene Expression Profiling for Superior Diagnosis of Idiopathic Giant-Cell Myocarditis and Clinical Feasibility in a Large Cohort of Patients with Acute Cardiac Decompensation (2020) (6)
Anticoagulant therapy in COVID-19 critically ill: Should we go for more? // Antithrombotische Therapie sehr kranker COVID-19-Patienten (2020) (6)
A Sex-Specific Analysis of the Predictive Value of Troponin I and T in Patients With and Without Diabetes Mellitus After Successful Coronary Intervention (2019) (6)
Difficult decision making in the management of patients with atrial fibrillation and acute coronary syndrome or invasive cardiovascular interventions: new recommendations for daily practice. (2015) (6)
Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE (2018) (6)
Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on Thrombosis. (2020) (6)
Clopidogrel pretreatment abolishes increase of PAI-1 after coronary stent implantation. (2008) (6)
Cardioprotective cytokine interleukin‐33 is up‐regulated by statins in human cardiac tissue (2018) (6)
Comparison of Short- and Long-term Results of Drug-Eluting vs. Bare Metal Stenting in the Porcine Internal Carotid Artery (2011) (6)
Antiplatelet therapy in percutaneous coronary intervention (2008) (6)
[Follow-up studies of routine health screening in Vorarlberg 1986-1994]. (1997) (6)
Effects of AV-delay optimization on hemodynamic parameters in patients with VDD pacemakers (2014) (6)
Data Sharing: A New Editorial Initiative of the International Committee of Medical Journal Editors. Implications for the Editors' Network. (2017) (6)
Coronary interventions in Austria, Germany, and Switzerland. (2020) (6)
Data Sharing: A New Editorial Initiative of the International Committee of Medical Journal Editors. Implications for the Editors' Network. (2017) (6)
Comparison of risk prediction models in infarct-related cardiogenic shock. (2021) (5)
Mid‐regional pro‐atrial natriuretic peptide independently predicts short‐term mortality in COVID‐19 (2021) (5)
Red Cell Distribution Width Upon Hospital Admission Predicts Short-Term Mortality in Hospitalized Patients With COVID-19: A Single-Center Experience (2021) (5)
The age of RCT`s 3 Important Aspects of RCT`s in Cardiovascular Pharmacotherapy with examples from Lipid and Diabetes Trials. (2019) (5)
New oral anticoagulant agents after ACS (2012) (5)
Corrigendum to: Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries (2014) (5)
Prasugrel vs. Ticagrelor in acute coronary syndromes: Which one to choose? (2011) (5)
Data Sharing: A New Editorial Initiative of the International Committee of Medical Journal Editors. Implications for the Editors´ Network. (2017) (5)
Parameters of the tissue factor pathway with coumadin/dipyridamole versus ticlopidine as adjunct antithrombotic-drug regimen in coronary artery stenting (2003) (5)
Defective fibrinolytic states as triggers of myocardial infarction: the cardiologist's view. (2001) (5)
[Platelet function: new drugs, new assays : possible impacts on operative medicine?]. (2012) (5)
Epinephrine treatment but not time to ROSC is associated with intestinal injury in patients with cardiac arrest. (2020) (5)
Pre‐hospital administration of ticagrelor in diabetic patients with ST‐elevation myocardial infarction undergoing primary angioplasty: A sub‐analysis of the ATLANTIC trial (2018) (5)
Circulating levels and prognostic cut‐offs of sST2, hs‐cTnT, and NT‐proBNP in women vs. men with chronic heart failure (2022) (5)
Admission proinsulin is associated with mortality in patients with admission hyperglycemia during acute coronary syndrome: results from a pilot observational study. (2011) (5)
Release of mitochondrial DNA is associated with mortality in severe acute heart failure (2020) (5)
Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry (2020) (5)
New-onset atrial fibrillation after percutaneous coronary intervention with stent: Updated proposal of an algorithm for the choice of oral anticoagulant and its dose. (2017) (5)
Critical appraisal of the 2020 ESC guideline recommendations on diagnosis and risk assessment in patients with suspected non-ST-segment elevation acute coronary syndrome (2021) (5)
EFFECT OF PROTON PUMP INHIBITORS ON OUTCOME OF PATIENTS DISCHARGED ON DUAL ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION AND STENT IMPLANTATION (2010) (5)
Fibrinolytic Response to Venous Occlusion Compared to Physical Stress Test in Young Patients with Coronary Artery Disease (1999) (5)
Safety and Efficacy of Ticagrelor Monotherapy According to Drug-Eluting Stent Type: The TWILIGHT-STENT Study. (2021) (5)
Diabetic specific aspects in antithrombotic therapy in patients with coronary artery disease. (2010) (5)
Associations between circulating proteins and corresponding genes expressed in coronary thrombi in patients with acute myocardial infarction. (2015) (5)
Impact of White Blood Cell Count on Clinical Outcomes in Patients Treated with Aspirin-Free Ticagrelor Monotherapy after Percutaneous Coronary Intervention: Insights from the GLOBAL LEADERS Trial. (2020) (5)
Data Sharing (2017) (5)
Authorship: from credit to accountability. Reflections from the Editors’ Network (2019) (4)
[Pathophysiological mechanisms of the renin-angiotensin system and its pharmacologic modification by ACE inhibitors or angiotensin II (type 1) receptor blockers in cardiovascular diseases]. (1997) (4)
Von Willebrand Factor and ADAMTS13 and long-term outcomes in patients undergoing percutaneous coronary intervention. (2020) (4)
The year in cardiovascular medicine 2021: acute cardiovascular care and ischaemic heart disease (2022) (4)
New approaches in plasminogen activator therapy. (1996) (4)
ESC Guidelines on the management of acute myocardial infarction with persistent ST-segment elevation (2012) (4)
Plasminogen activator inhibitor-1 plasma levels and coronary restenosis. (1992) (4)
Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism (2013) (4)
Long-term outcome in patients with takotsubo syndrome (2021) (4)
P2Y12-receptor-inhibiting antiplatelet strategies in acute coronary syndromes (2013) (4)
Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis. (2009) (4)
Authorship: From Credit to Accountability Reflections From the Editors´ Network (2019) (4)
Pre-existing anticardiolipin antibodies and development of restenosis after coronary balloon angioplasty: predictive value for a complicated course? (2004) (4)
Monocyte subsets predict mortality after cardiac arrest (2020) (4)
Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug‐Eluting Stent Implantation: Per‐Protocol Analysis of the GLOBAL LEADERS Trial (2022) (4)
[Persistent changes in tissue-type plasminogen activator and plasminogen activator inhibitor fibrinolytic parameters in patients following juvenile ischemic cerebral infarct]. (1988) (4)
Gender and Outcomes following Guided De-Escalation of Antiplatelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Gender Substudy (2018) (4)
P3-33: Analysis of tpte-interval for prediction of long term prognosis in cardiovascular disease (2006) (4)
Outcomes Associated with Respiratory Failure for Patients with Cardiogenic Shock and Acute Myocardial Infarction: A Substudy of the CULPRIT-SHOCK Trial (2020) (4)
Smoking and Outcomes Following Guided De-escalation of Antiplatelet Treatment in Acute Coronary Syndrome Patients: A Substudy from the Randomized TROPICAL-ACS Trial. (2019) (4)
The Role of Glycoprotein IIb/IIIa-Receptor Antagonists in Diabetics (2003) (4)
Gender-based differences of copeptin alone or combined with troponin for early rule-out of non-ST-elevation myocardial infarction. (2020) (4)
Effect of caffeine intake on platelet antigen levels of plasminogen activator inhibitor-1 (PAI-1) (1990) (4)
Impact of ultra-marathon and marathon on biomarkers of myocyte necrosis and cardiac congestion: a prospective observational study (2020) (4)
[Increased efficacy of thrombolytic therapy in acute myocardial infarction by improved properties of new thrombolytic agents]. (2000) (4)
Prediction of two-year survival and composite endpoints using the TIMI-7 risk score extended by N-terminal pro-brain natriuretic peptide levels (2003) (4)
Biomarkers Associated with Cardiovascular Disease in COVID-19 (2022) (4)
Effect of marathon and ultra‐marathon on inflammation and iron homeostasis (2020) (4)
Clopidogrel in coronary artery disease: update 2012. (2012) (4)
Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial (2020) (4)
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI (2022) (4)
Optimizing reperfusion therapy in acute ST-elevation myocardial infarction by a pharmaco-invasive treatment approach in a well-organized network. (2012) (4)
126 Complex formation between urokinase (uPA) and plasma protein C inhibitor (PCI) in vivo (1988) (4)
Abstract 13354: Pharmacodynamic Effects of Cangrelor and Clopidogrel: The Platelet Function Substudy from the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition in Patients Undergoing Percutaneous Coronary Intervention (CHAMPION-PCI) Trial (2011) (3)
Thrombolytic Therapy in Acute Myocardial Infarction (2000) (3)
The adipokine vaspin is associated with decreased coronary in-stent restenosis in vivo and inhibits migration of human coronary smooth muscle cells in vitro (2020) (3)
Guided de-escalation of DAPT in acute coronary syndrome patients undergoing percutaneous coronary intervention with BVS implantation: a post-hoc analysis from the randomized TROPICAL-ACS trial (2019) (3)
Was herzkranke Patienten über das Coronavirus (COVID-19) wissen sollten // COVID 19 – what heart patients need to know (2020) (3)
Circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with monocyte subsets in patients with stable coronary artery disease. (2021) (3)
Dual Antiplatelet Therapy Duration after Percutaneous Coronary Intervention using Drug Eluting Stents in High Bleeding Risk Patients: A Systematic Review and Meta-analysis. (2022) (3)
Toll like receptor 2 and 9 expression on circulating neutrophils is associated with increased mortality in critically ill patients. (2020) (3)
PCSK9 INHIBITION AND AORTIC STENOSIS IN THE FOURIER TRIAL (2020) (3)
Independent Predictors of Bleeding Complications in Patients Undergoing PCI With Concomitant Treatment With Bivalirudin in Clinical Practice Results From the Improver Registry (2013) (3)
Chlamydia pneumoniae in Carotid Artery Atherosclerosis (2002) (3)
[European National Society cardiovascular journals. Background, rationale and mission statement of the "editors' club"]. (2008) (3)
Fibrinolytic treatment of ST-elevation myocardial infarction (2013) (3)
[Consensus statement: Stroke prevention in nonvalvular atrial fibrillation in special consideration of the new direct oral anticoagulants]. (2014) (3)
Working Group on Thrombosis (2005) (3)
Association of Culprit Lesion Location With Outcomes of Culprit-Lesion-Only vs Immediate Multivessel Percutaneous Coronary Intervention in Cardiogenic Shock: A Post Hoc Analysis of a Randomized Clinical Trial. (2020) (3)
Hemostatic markers with bolus versus prolonged heparin after carotid artery stenting. (2003) (3)
Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial (2019) (3)
Antiplatelet therapy in atherothrombotic cardiovascular diseases for primary and secondary prevention: a focus on old and new antiplatelet agents. (2012) (3)
Acute coronary syndromes: recent achievements and future aspects (1998) (3)
[Direct anticoagulants for atrial fibrillation. Update 2014]. (2014) (3)
The role of European National Journals in Education. (2009) (3)
Angiographic predictors of outcome in myocardial infarction patients presenting with cardiogenic shock: A CULPRIT-SHOCK angiographic substudy. (2020) (3)
Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation (2022) (3)
Clinical Outcomes According to ECG Presentations in Infarct-Related Cardiogenic Shock in the Culprit Lesion Only PCI vs Multivessel PCI in Cardiogenic Shock Trial (3)
Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions. (2010) (3)
[Pre-hospital management of patients with chest pain and/or dyspnoea of cardiac origin.] (2017) (3)
Abstract 16714: Characterization of Types and Sizes of Myocardial Infarction Reduced With Evolocumab in FOURIER (2017) (3)
A microsatellite polymorphism in the Heme Oxygenase - 1 gene promoter is associated with increased serum bilirubin and HDl levels but not with a decreased risk for coronary artery disease (2003) (3)
Data Sharing: A New Editorial Initiative of the International Committee of Medical Journal Editors. Implications for the Editors' Network. (2017) (3)
New antithrombotic agents: an overview (1997) (3)
European National Society Cardiovascular Journals. Background, rationale and mission statement of the "Editors' Club". (2008) (3)
Time-related impact of distal embolisation on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation. (2012) (3)
Protease-Activated Receptors 1 and 3 are Differentially Expressed on Human Monocyte Subsets and are Upregulated by Lipopolysaccharide Ex Vivo and In Vivo (2019) (3)
Evaluation of the Age, Biomarkers, and Clinical History–Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials (2020) (3)
Comparative cross-over study of the effects of lisinopril and doxazosin on insulin, glucose and lipoprotein metabolism and the endogenous fibrinolytic system (1997) (3)
ECG Changes and Their Prognostic Impact in Patients With Takotsubo Syndrome (2019) (3)
Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarction. (2014) (2)
[Thrombolysis of acute myocardial infarct: modifying factors of "door-to-needle time"]. (1994) (2)
Early clinical outcomes as a function of use of newer oral P2Y12 inhibitors versus clopidogrel in the EUROMAX trial (2017) (2)
Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation". (2014) (2)
New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease (2022) (2)
Bivalirudin in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: uncertainties almost clarified. (2017) (2)
Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). (2018) (2)
["Inappropriate" thrombolysis in suspected myocardial infarct]. (2000) (2)
Midregional pro-A-type natriuretic peptide as part of a dual biomarker strategy for the early rule out of non-ST segment elevation acute coronary syndrome - The WilCop study. (2018) (2)
13N-ammonia rest/stress PET (2006) (2)
Relationship between plasma Neuregulin-1 and cardiac function in patients with ST-elevation myocardial infarction. (2022) (2)
Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization (2016) (2)
P4542Revisiting the obesity paradox in heart failure: percent body fat as predictor of biomarkers and outcome (2019) (2)
The adaptive immune system and long-term outcome in patients with stable coronary disease (2005) (2)
Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus (2012) (2)
Coronary Heart Disease Profibrinolytic , Antithrombotic , and Antiinflammatory Effects of an Insulin-Sensitizing Strategy in Patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes ( BARI 2 D ) Trial (2011) (2)
Copeptin as a part of the dual biomarker strategy for early diagnosis of non ST segment elevation myocardial infarction WILCOP study (2013) (2)
Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin (2021) (2)
In-Hospital Outcome Comparing Bivalirudin to Heparin in Real-World Primary Percutaneous Coronary Intervention. (2017) (2)
Clopidogrel Salts - Pharmacokinetic, Pharmakodynamic and Clinical Aspects (2009) (2)
Coronary artery calcium (CAC) score - a prognostic tool in coronary artery disease? (2011) (2)
Plasminogen activator inhibitor-1 and transient myocardial ischemia (1989) (2)
Endpoint design for future renal denervation trials - Novel implications for a new definition of treatment response to renal denervation. (2016) (2)
Platelet antiaggregation after an acute coronary syndrome: what about the elderly? (2022) (2)
Data Sharing: A New Editorial Initiative of the International Committee of Medical Journal Editors. Implications for the Editors' Network. (2017) (2)
Conflict of interest policies and disclosure requirements among European Society of Cardiology national cardiovascular journals (2012) (2)
Multisystem inflammatory syndrome in adults in a young male following severe acute respiratory syndrome coronavirus-2 infection: a case report (2021) (2)
Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial (2020) (2)
Lowering blood pressure in primary care in Vienna (LOW-BP-VIENNA) (2018) (2)
Comparing TEE‐ vs Non–TEE‐guided cardioversion of atrial fibrillation: The ENSURE‐AF trial (2020) (2)
Valvuloplasty with a paclitaxel-eluting balloon prevents restenosis in an experimental animal model of aortic stenosis. (2014) (2)
Pharmacologic modulation of intracellular Na+ concentration with ranolazine impacts inflammatory response in humans and mice (2022) (2)
Systems of care for patients with acute ST elevation myocardial infarction (STEMI networks) (2018) (2)
ApPropRiateness of myOcardial revascUlarization assessed by SYNTAX Scores in patients with type 2 diabetes melliTus: the PROUST study* (2020) (2)
Clinical outcomes according to ECG presentations in infarct-related cardiogenic shock in CULPRIT-SHOCK. (2020) (2)
[Periprocedual management of vitamin K antagonist's with low molecular weight heparins during invasive procedures--Consensus of experts]. (2013) (1)
SOLUBLE SELECTINS IN THE PULMONARY AND SYSTEMIC CIRCULATION IN ACUTE CARDIOGENIC AND IN NON CARDIOGENIC PULMONARY FAILURE: EVIDENCE OF PULMONARY ENDOTHELIAL ACTIVATION DURING CARDIOGENIC PULMONARY EDEMA (CPE). (1999) (1)
Prognostic value of sST2 in heart failure patients with diabetes (2021) (1)
Underuse of reperfusion therapy in female patients: Insights from the TETAMI study and registry (The safety and efficacy of subcutaneous Enoxaparin versus intravenous unfractionated heparin and of myocardial infarction) (2003) (1)
P5602Impact of preprocedural TIMI flow on clinical outcome in low-risk patients with ST-elevation myocardial infarction: results from the ATLANTIC study (2018) (1)
CIRCULATING MITOCHONDRIAL DNA IS ASSOCIATED WITH MORTALITY IN PATIENTS WITH ACUTE HEART FAILURE (2017) (1)
Limitation of vWf meta-analysis in LMWH comparison. (2001) (1)
Cardiac inflammation associated with COVID-19 mRNA vaccination in patients with and without previous myocarditis. (2023) (1)
Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis (2021) (1)
P1724Prognostic impact of atrial fibrillation in acute myocardial infarction and cardiogenic shock: results from the CULPRIT-SHOCK trial (2019) (1)
The effect of p 22-PHOX ( CYBA ) polymorphisms on premature coronary artery disease ( ≤ 40 years of age ) (2018) (1)
Diagnostic evaluation of the new Sgx clarity ultrasensitivity troponin I assay in patients with suspected myocardial infarction (1)
COPEPTIN AS A PART OF THE DUAL BIOMARKER STRATEGY FOR EARLY DIAGNOSIS OF NSTEMI: WILCOP STUDY (2013) (1)
Neurotensin and Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention (2022) (1)
Balance of Benefit and Risk of Ticagrelor in Patients With Diabetes and Stable Coronary Artery Disease According to Bleeding Risk Assessment With the CRUSADE Score: Data From THEMIS and THEMIS PCI: Abbreviated title: Bleeding risk stratification of ticagrelor. (2022) (1)
Sex-based differences of copeptin for early rule-out of non-ST-elevation myocardial infarction (2020) (1)
Authorship: From credit to accountability. Reflections from the Editors' Network. (2019) (1)
PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 (PAI-1), ORGAN FAILURE AND OUTCOME AFTER SUCCESSFUL CARDIOPULMONARY RESUSCITATION (CPR) (1999) (1)
Impact of Center Volume on Outcomes in Myocardial Infarction Complicated by Cardiogenic Shock: A CULPRIT‐SHOCK Substudy (2021) (1)
41 Circulating levels and prognostic cut-offs of sST2, high-sensitivity troponin T, and NT-proBNP in women vs. men with chronic heart failure (2021) (1)
Association between smoking and presence of mycoplasma pneumoniae in circulating leukocytes. (2010) (1)
Psychocardiological assessment in the acute phase of the takotsubo syndrome (2021) (1)
Scores for outcome prediction in patients admitted with cardiogenic shock. (2021) (1)
P3568Low apolipoprotein a1 is significantly associated with decreased risk of cardiovascular events in anticoagulated patients with atrial fibrillation: insights from the ARISTOTLE trial (2017) (1)
Das Tako-Tsubo-Syndrom – die stressinduzierte Kardiomyopathie // Takotsubo Syndrome – stress-induced Cardiomyopathy (2019) (1)
Data Sharing: A New Editorial Initiative of the International Committee of Medical Journal Editors. Implications for the Editors´ Network (2017) (1)
COPEPTIN AND HIGH-SENSITIVITY TROPONIN I IN PATIENTS WITH CHEST PAIN AND RECENT SYNCOPE (2017) (1)
Effects of ON-Hours Versus OFF-Hours Admission on Outcome in Patients With Myocardial Infarction and Cardiogenic Shock (2020) (1)
European National Society Cardiovascular Journals. Background, rationale and mission statement of the "Editors' Club" (Task Force of the European Society of Cardiology). (2009) (1)
Immature cell fractions after cessation of chronic P2Y12-inhibition in patients with coronary artery diseases (2020) (1)
COPEPTIN LEVELS IN PATIENTS WITH CHEST PAIN WITH TYPE -1 AND TYPE-2 MYOCARDIAL INFARCTION (2016) (1)
Abstract 14839: Transesophageal Echocardiography-Guided Strategy vs Conventional Anticoagulation for Cardioversion of Atrial Fibrillation: An Analysis of Thromboembolic and Bleeding Events From the ENSURE-AF Study (2018) (1)
The role of European national journals in education. (2009) (1)
[Inhibition of the renin-angiotensin system: ACE inhibitors and angiotensin II receptor blockers]. (1996) (1)
Fostering diffusion of scientific contents of national society cardiovascular journals: the new ESC search engine. (2013) (1)
Biomarkers-in-Cardiology 8 RE-VISITED—Consistent Safety of Early Discharge with a Dual Marker Strategy Combining a Normal hs-cTnT with a Normal Copeptin in Low-to-Intermediate Risk Patients with Suspected Acute Coronary Syndrome—A Secondary Analysis of the Randomized Biomarkers-in-Cardiology 8 Trial (2022) (1)
Bivalirudin use in patients undergoing percutaneous coronary intervention for acute myocardial infarction. Insights from the prospective, multi-centre EUROVISION registry (2014) (1)
IMPACT OF P2Y12 INHIBITOR CHOICE ON 30-DAY OUTCOMES AFTER PRIMARY PCI: AN ANALYSIS FROM THE EUROMAX TRIAL (2014) (1)
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index. (2022) (1)
Anticoagulants in Heart Disease Position Paper Syndromes: ESC Working Group on ThrombosisTask Force on New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary (2012) (1)
Opposite effects of CX3CR1 receptor polymorphismsV249I andT280Mon the development of acute coronary syndrome A possible implication of fractalkine in inflammatory activation (2017) (1)
Prasugrel in Clopidogrel Nonresponders: A Way to Improve Secondary Prevention in Patients After Percutaneous Coronary Intervention? (2015) (1)
Abstract 11043: Clinical Safety Outcomes in Relation to Lipoprotein(a) Concentration: Insights from the FOURIER Trial (2021) (1)
Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin (2021) (1)
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. (2022) (1)
Prostaglandin E1 induces vascular endothelial growth factor-A in human adult cardiac myocytes and coronary artery smooth muscle cells (2003) (1)
Peri-interventional Triple Therapy With Dabigatran Improves Vasomotion and Promotes Endothelialization in Porcine Coronary Stenting Model (2021) (1)
Testing Drug Eluting Paclitaxel Balloon Valvuloplasty in an Experimental Model of Aortic Stenosis (2014) (1)
Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease. (2021) (1)
Abstract 15115: Reduction in Bleeding with Apixaban versus Warfarin is Consistent Across Subgroups and Locations: Insights from the ARISTOTLE Trial (2012) (1)
551Effects of interleukin-33 on tissue factor in human endothelial cells in vitro (2014) (1)
Soluble neprilysin and survival in critically ill patients (2021) (1)
EARLY STENTING VERSUS CONSERVATIVE TREATMENT AFTER SUCCESSFUL FIBRINOLYSIS FOR STEMI: RESULTS OF THE RANDOMIZED ANGIOGRAPHIC APRICOT-3 TRIAL (2012) (1)
Subgroup analyses in randomized clinical trials: Value and limitations Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. (2021) (1)
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. (2022) (1)
[Lipid profiles and therapy status in the secondary prevention of high risk patients with cardiovascular disease and/or diabetes mellitus: the Austrian Hospital Screening Project (HSP)]. (2008) (1)
The Association for Acute Cardiovascular Care. (2020) (1)
CLINICAL UTILITY OF BIOMARKERS TO PREDICT STENT THROMBOSIS AFTER STEMI TREATED WITH DES: A HORIZONS-AMI SUBSTUDY WITH 3-YEAR FOLLOW-UP (2011) (1)
Antithrombotic Therapy in ST‐Segment Elevation Myocardial Infarction (2012) (1)
The year in cardiovascular medicine 2022: the top 10 papers in acute cardiac care and ischaemic heart disease. (2023) (1)
APPROPRIATENESS OF MYOCARDIAL REVASCULARIZATION ASSESSED BY SYNTAX SCORE II IN A CENTRE WITHOUT ON-SITE CARDIAC SURGERY (2015) (1)
Resumption of Antiplatelet Therapy after Major Bleeding (2022) (1)
Thrombolysis - a rapidly moving target of antithrombotic therapy: a preface (1995) (1)
Culprit lesion location and outcomes in patients with multi-vessel disease and infarct-related cardiogenic shock. A core laboratory analysis of the CULPRIT-SHOCK trial. (2020) (1)
The role of European National Journals in education. (2009) (1)
Association of Plasma Methylglyoxal Increase after Myocardial Infarction and the Left Ventricular Ejection Fraction (2022) (1)
Application of the fourth universal definition of myocardial infarction in clinical practice (2020) (1)
Influence of Culprit Lesion Intervention on Outcomes in Infarct-Related Cardiogenic Shock With Cardiac Arrest. (2023) (1)
Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial (2022) (1)
Basic mechanisms in cardiogenic shock: part 1-definition and pathophysiology. (2022) (1)
Abstract 569: NT-proBNP is an Important Independent Predictor of Clinical Events after Primary PCI for STEMI (2008) (1)
P1725Current spectrum and 1-year mortality of cardiogenic shock in Europe. Results of the CULPRIT-SHOCK randomized clinical trial and registry (2019) (0)
548 TYPE 2 DIABETES AND THE PROGRESSION OF VISUALIZED ATHEROSCLEROSIS TO CLINICAL CARDIOVASCULAR EVENTS (2011) (0)
Prognostic value of NT-proBNP and best cut-offs for risk prediction in obese patients with chronic systolic heart failure (2020) (0)
European National Society Cardiovascular Journals. Background, rationale and mission statement of the "Editors' Club" (Task Force of the European Society of Cardiology). (2008) (0)
1011-112 Use of abciximab prior to primary angioplasty in ST-segment elevation myocardial infarction results in early recanalization of the infarct-related artery: Results of the multicenter randomized ReoPro-BRIDGING study (2004) (0)
P542Human monocyte subsets differentially express tissue factor in vivo and in vitro (2018) (0)
Comparing Outcome of Cardiac Catheterization in March 2020 with March 2019 (2020) (0)
Presentation, care and outcomes of patients with NSTEMI according to World Bank country income classification: Prospective international multicentre cohort study of the ESC EORP NSTEMI registry (2023) (0)
Data sharing: A new editorial initiative of the International Committee of Medical Journal Editors. Implications for the editors’ network☆ (2017) (0)
P3389Mitochondrial DNA predicts mortality in acute but not in chronic heart failure (2017) (0)
86 Relevance of serial measurements of N‐terminal‐pro‐brain natriuretic peptide in an outpatients ward for heart failure (2007) (0)
174. Elevated plasma levels of C-reactive protein are predictors of late restenosis after coronary angioplasty (1996) (0)
P3689Levels of platelet micro-RNA-223, microRNA-150 and microRNA-21 in patients with coronary artery disease during dual anti platelet therapy and after cessation of P2Y12-inhibitor therapy (2017) (0)
P3669Smoking and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients: the TROPICAL-ACS smoking substudy (2018) (0)
The gp130 ligand Oncostatin M contributes to stem cell homing via induction of SDF‐1 in cardiac cells. (2006) (0)
P338Statin treatment reduces matrix degradation capacity of proinflammatory polarized macrophages (2018) (0)
Abstract 12130: Outcomes in Women Compared With Men in Patients With Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction Managed Without Revascularization: Insights From the TRILOGY ACS Trial (2013) (0)
Abstract 2165: Coronary Instent Restenosis of Drug-Eluting Stents is Associated with Serum Levels of MMP-9 (2007) (0)
P4587Impact of diabetes mellitus on myocardial revascularisation method in the light of the 2018 ESC/EACTS guidelines: Results from the PROUST Study (2019) (0)
ECG changes and wall motion abnormalities in the acute phase of takotsubo syndrome (2013) (0)
2.P.130 Urinary excretion of apo(a) in patients after kidney transplantation (1997) (0)
ID: 65 PLASMINOGEN ACTIVATOR INHIBITOR-1 PLASMA LEVELS ARE ASSOCIATED WITH CORONARY INSTENT RESTENOSIS OF DRUG ELUTING STENTS (2006) (0)
P1741Copeptin plasma level in type 1 and type 2 myocardial infarctions (2018) (0)
Peri-Interventional Triple Therapy with Dabigatran Modifies Vasomotion after Bare-Metal Stent Implantation in a Pig Coronary Artery Model (2023) (0)
Response to: "Arrhythmia paradox in patients with familial hypercholesterolemia". (2019) (0)
Pathophysiological Basis of the Acute Coronary Syndromes (2000) (0)
Abstract 19062: Copeptin-to-BUN Ratio Predicts Outcome in Patients with Advanced Heart Failure: A key to the use of vasopressin antagonists? (2012) (0)
Abstract 3040: Plasminogen Activator Inhibitor-1 Plasma Levels are associated with Coronary Instent Restenosis of Drug-Eluting Stents (2006) (0)
Member of the Awareness , Behandlung und Kontrolle von Hypertonie in Österreich / / Awareness , treatment and control of hypertension in Austria – A multicentre cross-sectional study (2016) (0)
PLASMINOGEN ACTIVATOR INHIBITOR-1 IS REGULATED BY GLYCOPROTEIN 130 LIGANDS IN HUMAN ADIPOSE TISSUE (2004) (0)
Relation of Nt-proBNP and time to treatment to outcome of patients with ST-elevation myocardial infarction: an ASSENT IV-PCI substudy (2008) (0)
ConfliC t of interest poliCies and dis Closure requirements among european s oCiety of Cardiology national Cardiovas Cular journals (2012) (0)
Cohort Profile: The ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry. (2022) (0)
P4604Residual stroke risk of anticoagulated patients with atrial fibrillation: PREFER in AF European registry (2017) (0)
Lower pacemaker implantation rates for atrioventricular block during COVID-19 (2021) (0)
Abstract 2672: Serial in vivo Non-invasive Imaging of Intramyocardially Injected Autologous Mesenchymal Stem Cells, Modified for Transgene Expression of Positron-Emission Tomography (PET) Reporter in Porcine Myocardial Infarction (2007) (0)
Abstract 15930: Circulating Levels of Proprotein Convertase Subtilisin/kexin Type 9 (pcsk9) are Associated With Monocyte Subsets in Patients With Stable Coronary Artery Disease (2020) (0)
ID: 258 In vitro effects of two new drugs, Bivalirudin and Desmoteplase, on clot lysis. A comparison with drugs currently used in thrombolysis and revascularisation (2006) (0)
Long-term outcomes for women vs. men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: Insights from the TRILOGY ACS trial (2015) (0)
306 Plasminogen activator inhibitor (PAI-1) levels in plasma of patients with chronic angina pectoris with or without coronary artery sclerosis (1988) (0)
Intermediate density lipoprotein is associated with monocyte subset distribution in patients with stable atherosclerosis (2016) (0)
P252Plasma osmolality predicts clinical outcome in patients with acute coronary syndrome undergoing percutaneous coronary intervention (2014) (0)
29 Fibrinolytic parameters and patency rate after thrombolysis with recombinant tissue plasminogen activator (rtPA) in patients with acute myocardial infarction (AMI) (1988) (0)
Protease‐activated receptor‐mediated platelet aggregation in patients with type 2 diabetes on potent P2Y 12 inhibitors (2021) (0)
P1502Open-label ODYSSEY APPRISE study: interim data from the first 843 participants (2017) (0)
Facilitation of primary PCI with ReoPro: reply (2005) (0)
EXTRACELLULAR ADHERENCE PROTEIN OF STAPHYLOCOCCUS AUREUS INHIBITS ATHEROSCLEROSIS IN APOE-DEFICIENT MICE (2014) (0)
[Acute coronary syndromes: physiopathology and therapeutic aspects]. (1999) (0)
78. The role of plasminogen activator inhibitor type-1 (PAI-1) in acute coronary syndromes (1996) (0)
BleedingandstentthrombosisonP 2 Y 12-inhibitors : collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention (2015) (0)
P3515Gender differences in plasma levels and prognostic value of NT-proBNP in chronic heart failure (2019) (0)
341 Trends in hospitalization due to Congestive feart failure in Austria, 1990-2004 (2008) (0)
European Perspectives in Cardiology European Perspectives in Cardiology (2011) (0)
experience Network models for large cities : the European (2009) (0)
Abstract 13270: Relationship of Longitudinal Measurements of Biomarkers of Hemodynamic Stress, Systemic Inflammation, and Platelet Reactivity with Ischemic Outcomes in Non-ST-Elevation Acute Coronary Syndrome Patients Managed Without Revascularization (2014) (0)
Reply: Transfemoral Transcatheter Aortic Valve Replacement and On-Site Cardiac Surgery: More Than a Simple Debate About the Heart Team. (2019) (0)
Corrigendum to "Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention" [Atherosclerosis 270 (2018) 173-179]. (2020) (0)
Verursachen P2Y12-Inhibitoren solide Tumore? Eine Analyse // Do P2Y12-inhibitors cause Solid Tumours? An Analysis (2019) (0)
What is new in the 2016 European Society of Cardiology atrial fibrillation guidelines (2017) (0)
P1003Effect of concomitant antiplatelet agents on clinical outcomes in the Edoxaban versus Warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial (2018) (0)
P771Impact of platelet turnover on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention (2018) (0)
Abstract 1948: Monocyte Chemoattractant Protein 1 And Macrophage Colony Stimulating Factor Are Markers Of Adverse Outcome In Heart Failure Patients. (2007) (0)
Acute Cardiovascular Care-Clinical Cases (2018) (0)
University of Birmingham Net clinical benefit of non-vitamin K antagonist vs vitamin K antagonist anticoagulants in elderly patients with atrial fibrillation (2019) (0)
Risk reduction strategies: perioperative management in patients on antithrombotic therapy (2018) (0)
Conflict of interest policies and disclosures in Journals (2012) (0)
Effects of diet and/or n-3 fatty acid supplementation on components of the interleukin-6 trans-signalling system in elderly men (2015) (0)
Long-Term Effects of Renal Denervation on Blood Pressure Burden in Patients with Resistant Arterial Hypertension (2016) (0)
The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials. (2020) (0)
ID: 252 Thrombin upregulates expression of oncostatin M (OSM) in human macrophages and peripheral blood monocytes. (2006) (0)
Abstract 21285: Copeptin and Nt-proBNP as Precitors of Post-operative Outcome in Patients with Major Vascular Surgery (2010) (0)
Acute coronary syndromes and COVID-19 pandemic (2020) (0)
Percutaneous coronary intervention (2014) (0)
A decade of acute cardiovascular care: an association worth celebrating. (2022) (0)
Chapter 40 Systems of care for patients with acute coronary syndrome (2010) (0)
Magnesium profile in vasospastic angina (1989) (0)
TICAGRELOR MONOTHERAPY AFTER PCI ACROSS THE SPECTRUM OF HIGH-RISK PATIENTS: A DEEP DIVE INTO THE TWILIGHT TRIAL (2022) (0)
P1147Complications in young ICD patients - a retrospective analysis (2020) (0)
Neutrophile-Lymphocyte Ratio and Outcome in Takotsubo Syndrome (2022) (0)
Abstract 18190: Impact of Age and Gender on Clinical Outcomes in the Edoxaban versus Warfarin in Subjects Undergoing Cardioversion of Atrial Fibrillation (ENSURE-AF) Randomized Trial (2017) (0)
Prasugrel compared to ticagrelor in primary PCI (2020) (0)
MONOCYTE SUBSET DISTRIBUTION IS ASSOCIATED WITH OUTCOME IN PATIENTS AFTER CARDIAC ARREST (2020) (0)
P5376Interleukin-33 stimulates the release of procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets (2017) (0)
PRO-APOPTOTIC EFFECT OF HYDROXYMETHYLGLUTARYL-COENZYME A REDUCTASE INHIBITORS ON HUMAN MUSCLE CELLS IN VITRO (2004) (0)
Ticagrelor With or Without Aspirin in High-Risk Patients With Anemia Undergoing Percutaneous Coronary Intervention: a subgroup analysis of the TWILIGHT trial. (2023) (0)
Awareness, Behandlung und Kontrolle von Hypertonie in Österreich // Awareness, treatment and control of hypertension in Austria – A multicentre cross-sectional study (2016) (0)
and In Vivo (2017) (0)
THE COMPLEMENT COMPONENT C5A INDUCES THE EXPRESSION OF MATRIX METALLOPROTEINASE-1 AND PLASMINOGEN ACTIVATOR INHIBITOR-1 IN HUMAN MACROPHAGES (2004) (0)
EFFECTS OF HYDROXYMETHYLGLUTARYL-COENZYME A REDUCTASE INHIBITORS ON COMPONENTS OF THE FIBRINOLYTIC SYSTEM AND ON THE INFLAMMATORY MEDIATOR MCP-1 IN HUMAN CARDIAC MYOCYTES IN VITRO (2004) (0)
Pharmacist interventions to improve blood pressure control in primary care: a cluster randomised trial (2022) (0)
OP-85 Trends in Hospitalization Due to Congestive Hear Failure in Austria, 1989 – 2013 (2015) (0)
Meta-Analysis of Anticoagulation Therapy for the Prevention of Cardiovascular Events in Patients with Peripheral Arterial Disease. (2021) (0)
Das "Reduction of Atherothrombosis for Continued Health-(REACH-) Register": Basisdaten der österreichischen Population (2019) (0)
COVID-19-Cardiac aspects (2020) (0)
The role of European national journals in education. (2009) (0)
RELATIONSHIP BETWEEN ARTERIAL ACCESS AND OUTCOMES IN A PHARMACOINVASIVE VERSUS PRIMARY PCI STRATEGY IN ST-ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION (STREAM) STUDY (2015) (0)
PLASMA OSMOLALITY PREDICTS CLINICAL OUTCOME IN PATIENTS ADMITTED WITH ACUTE CORONARY SYNDROME UNDERGOING PCI AND STENT IMPLANTATION (2013) (0)
203The expression of pro-coagulatory endothelial- and monocyte derived extracellular vesicles in patients with coronary artery disease differs depending on the presence of certain cardiovascular risk fac (2018) (0)
Dual antiplatelet therapy: short or long after acute coronary syndrome? (2017) (0)
Impact of body size on platelet function in patients with acute coronary syndrome on dual antiplatelet therapy. (2022) (0)
The LIPL study lipid panels and platelet activity in coronary heart disease (2022) (0)
Plättchenhemmer in der Primär- und Sekundärprävention bei kardiovaskulären Erkrankungen // Platelet inhibitors in primary and secondary prevention of cardiovascular disease (2019) (0)
Atherothrombosis n Increase of C-Reactive rotein Is Associated With Enhanced ctivation of Endogenous Fibrinolysis t Baseline But an Impaired Endothelial ibrinolytic Response After Venous Occlusion alter (2016) (0)
The role of European national journals in education. (2009) (0)
PAI-1 expression renders M2 polarized macrophages proteolytically quiescent (2016) (0)
Authorship: From credit to accountability - Reflections from the Editors' network. (2019) (0)
Circulation: Cardiovascular Quality and Outcomes (2021) (0)
EFFECT OF PROTON PUMP INHIBITORS ON CLINICAL OUTCOME IN PATIENTS TREATED WITH CLOPIDOGREL: A SYSTEMATIC REVIEW AND META-ANALYSIS (2010) (0)
Is Treatment of ST-Segment-Elevation Myocardial Infarction Patients With Ticagrelor or Other P2Y12 Inhibitors Before Primary Percutaneous Coronary Intervention a Strategy Without Benefit? (2018) (0)
Ticagrelor monotherapy beyond 1 month versus standard dual antiplatelet therapy after drug-eluting coronary stenting: a pre-specified per-protocol analysis of the GLOBAL LEADERS trial (2020) (0)
Translational Medicine on the Road to Tailored Therapies (2014) (0)
PP.26.20: EFFECT OF PERCUTANEOUS RENAL DENERVATION ON INFLAMMATORY MARKERS (2015) (0)
PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRACER TRIAL (2012) (0)
Effect of aspirin discontinuation according to individualised patient bleeding and ischemic risks after PCI: a TWILIGHT trial sub-analysis (2022) (0)
Patients with resistant arterial hypertension - is there an effect of percutaneous renal denervation on inflammation markers in responders? (2015) (0)
Subject Index Vol. 108, 2007 (2007) (0)
A role for gp130‐ligands in angiogenesis: Oncostatin M upregulates its own receptors and angiopoietin2 in human endothelial cells (2006) (0)
Acute Coronary Syndromes PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRA·CER TRIAL (2012) (0)
Changes and innovations of the 2017 ESC guidelines on dual antiplatelet therapy in coronary artery disease—a review (2018) (0)
Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of glassy and twilight. (2023) (0)
VASCULAR ENDOTHELIAL GROWTH FACTOR IS INCREASED BY GLYCOPROTEIN 130 LIGANDS IN HUMAN ADIPOSE TISSUE (2004) (0)
Presentation, care and outcomes of patients with NSTEMI according to World Bank country income classification: the ACVC-EAPCI EORP NSTEMI Registry of the European Society of Cardiology. (2023) (0)
Coagulation and thrombosis (2017) (0)
Trends in Hospitalization Due to Congestive Heart Failure in Austria, 1990–2004 (2007) (0)
Adjusting device for a mechanical lever assembly, in particular of an embroidery machine and the use of this locking device (1982) (0)
CIRCULATING LEVELS OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK-9) ARE ASSOCIATED WITH MONOCYTE SUBSETS IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE (2020) (0)
Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how (2022) (0)
Abstract 1710: Markers Of Apoptosis And Prognosis Of Chronic Heart Failure Patients (2007) (0)
experiencemodels for large cities: the European (2010) (0)
THE IMPACT OF BIVALIRUDIN AND OTHER PERI-INTERVENTIONAL ANTITHROMBOTIC STRATEGIES ON ALL-CAUSE MORTALITY IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PCI PLUS CORONARY STENTING (2013) (0)
[GP IIb/IIIA inhibitors in the treatment of patients with coronary heart disease] (2003) (0)
Laboratory monitoring of success and failure of thrombolytic therapy in acute myocardial infarction (1995) (0)
P2267De-escalation of antiplatelet therapy after percutaneous coronary intervention in acute coronary syndrome patients: outcome of diabetics in the randomized TROPICAL-ACS trial (2018) (0)
Long-term effects of renal denervation on blood pressure burden in ambulatory blood pressure measurements in patients with resistant arterial hypertension (2015) (0)
Direct and indirect antithrombins in acute coronary syndromes (2005) (0)
A22-2 Longterm follow-up of single-lead-VDD-pacing (2003) (0)
3293Atherothrombotic risk and outcomes following guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome:a post-hoc analysis of the TROPICAL-ACS trial (2019) (0)
Plasma levels of u-PA and SCU-PA in patients suffering from coronary heart disease (1994) (0)
1165-105 Exercise training reduces vascular inflammation in patients with cardiovascular risk or disease (2004) (0)
MYOCARDIAL ISCHEMIA AND INFARCTION RELATIONSHIP BETWEEN BIOMARKERS AND SUBSEQUENT MAJOR ADVERSE CARDIOVASCULAR EVENTS AFTER ST-ELEVATION MYOCARDIAL INFARCTION: A HORIZONS-AMI SUBSTUDY (2011) (0)
1098-101 Risk stratification in unstable angina/non-ST elevation myocardial infarction using plasma N-terminal pro-atrial natriuretic peptide, troponin I and high-sensitive C-reactive protein levels (2004) (0)
2190Prevalence, management and prognostic impact on long-term mortality of familial hypercholesterolemia in patients with acute or stable coronary artery disease (2017) (0)
TCT-777 Guided De-Escalation of DAPT in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention with BVS implantation: A post-hoc Analysis from the Randomized TROPICAL-ACS Trial (2018) (0)
W08-P-026 Hepatocyte growth factor mediates induction of PAI-I, IL-6 and IL-8 in human adipose tissue (2005) (0)
TCT-112 Patient-oriented clinical outcomes and net adverse cardiovascular event in the Global Leaders trial (2018) (0)
TCT-13 Ticagrelor Monotherapy in Patients With Peripheral Artery Disease Undergoing PCI (2022) (0)
AGE AND OUTCOMES FOLLOWING GUIDED DE-ESCALATION OF ANTIPLATELET TREATMENT IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: RESULTS OF A RANDOMIZED MULTICENTRE TRIAL (2018) (0)
Abstract 2087: Plasma Interleukin - 6 and Nt-proBNP Levels are Strong and Independent Predictors of Outcome in Patients with Cardiogenic Shock (2006) (0)
GENDER DIFFERENCES IN SHORT- AND LONG-TERM MORTALITY IN THE VIENNA STEMI REGISTRY (2017) (0)
Abstract 17232: The Adipokine Vaspin Inhibits Smooth Muscle Migration in vitro and the Development of Coronary in-Stent Restenosis in vivo (2010) (0)
Authorship: From credit to accountability - Reflections from the Editors' network. (2019) (0)
Update in thrombolysis, arteriosclerosis, thrombosis and cardiovascular biology, update in cardiovascular hemostasis, 1998, 8-10 October 1998, Berlin, Germany (1998) (0)
Cangrelor in patients with PCI for acute myocardial infarction after cardiac arrest and/or with cardiogenic shock. (2023) (0)
P169Circulating micro RNAs identify patients at increased risk of in-stent restenosis after peripheral angioplasty with stent implantation (2018) (0)
Complex Formation Between Urokinase and Plasma Protein C Inhibitor In Vitro (2005) (0)
P107Cardioprotective cytokine interleukin-33 is upregulated by statins and bisphosphonates in human cardiac cells (2018) (0)
Sex Difference in Bleeding Risk With P2Y12 Inhibitor Agents After Percutaneous Coronary Intervention-Reply. (2022) (0)
Human cardiac cells express GM-CSF under inflammatory conditions—possible implications for cell differentiation and angiogenesis (2006) (0)
Kongressbericht: Highlights vom 11. Great Minds Œ European PCI Expert Meeting, 23.Œ24. Juni 2017 in Budapest (2018) (0)
Improved in-hospital outcome for radial access in a large contemporary cohort of primary percutaneous coronary intervention. (2021) (0)
Is diversity harmful?—Mixed-brand cardiac implantable electronic devices undergoing magnetic resonance imaging (2021) (0)
Clopidogrel Salts Clopidogrel Salts – Pharmacokinetic , Pharmacodynamic and Clinical Aspects (2018) (0)
TCT-111 Efficacy and safety of glycoprotein IIb/IIIa inhibitors on top of a potent P2Y12 inhibitor in STEMI: A pre-specified sub-analysis of the ATLANTIC trial (2018) (0)
European Society of Cardiology Working Groups. Working Group 18: Thrombosis. Interview by Emma Wilkinson. (2007) (0)
Improvement of Antiplatelet Therapy in Acute Coronary Syndromes by Prasugrel, a New Adenosine Diphosphate-Receptor Inhibitor (2011) (0)
P6227Prognostic impact of soluble p-selectin on long-term adverse cardiovascular outcome in patients with acute and stable coronary artery disease (2017) (0)
Current Definitions of Non-ST-Segment Elevation Myocardial Infarction: Challenges for Further Improvement. (2018) (0)
Data sharing : implications for the Editors ’ Network (2017) (0)
SOLUBLE ADHESION MOLECULES, THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) AND OUTCOME AFTER SUCCESSFUL CARDIOPULMONARY RESUSCITATION (CPR) (1999) (0)
A role for gp130-ligands in angiogenesis: Oncostatin M regulates angiopoietin1, angiopoietin2 and its own receptors in human endothelial cells (2006) (0)
Abstract 3132: High Soluble Fas Plasma Levels Are Protective After Stent Implantation (2007) (0)
Pacemaker implantation rates during COVID-19 (2020) (0)
B-TYPE NATRIURETIC PEPTIDE AND THE RISK OF CONTRAST INDUCED NEPHROPATHY IN STEMI: ANALYSIS FROM THE HORIZONS-AMI TRIAL (2012) (0)
CATECHOLAMINES SYNERGISTICALLY INCREASE LIPOPOLYSACCHARIDE-INDUCED EXPRESSION OF MATRIX METALLOPROTEINASE-1 AND MATRIX METALLOPROTEINASE-9 IN HUMAN MONOCYTES (2004) (0)
the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion of Intervention for Acute ST-Segment Elevation Myocardial Infarction: Results Effect of Intravenous FX06 as an Adjunct to Primary Percutaneous Coronary (2009) (0)
TICAGRELOR MONOTHERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN HIGH-RISK PATIENTS WITH OR WITHOUT HISTORY OF MYOCARDIAL INFARCTION. A PRESPECIFIED TWILIGHT SUBSTUDY (2021) (0)
Stroke and recurrent left atrial appendage thrombus in a patient with atrial fibrillation under old and new oral anticoagulants: A case report (2013) (0)
RELATIONSHIP BETWEEN BIOMARKERS AND SUBSEQUENT ADVERSE ISCHEMIC AND BLEEDING EVENTS AFTER ST-ELEVATION MYOCARDIAL INFARCTION: A HORIZONS-AMI SUBSTUDY (2011) (0)
Consensus Report 281 (2019) (0)
High PAI-1 Levels as Marker of Rethrombosis after Successful Coronary Balloon Angioplasty (2019) (0)
Comparison of number and clinical outcome of acute coronary syndromes before, during and after the lockdown in the COVID-19 Pandemic (2020) (0)
Abstract 20764: Efficacy and Safety of Clopidogrel 600mg Administered Prehospital to Improve Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: Final Results of the Randomized CIPAMI Trial. (2010) (0)
acute phase of myocardial infarction Insufficient secretion of atrial natriuretic peptide at (2015) (0)
ADP-receptor antagonists in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis (2021) (0)
Reply to letter to the editors: The long-term prognosis of patients with takotsubo syndrome (2022) (0)
Glycoprotein 130 mediated induction of vascular endothelial growth factor in human adult cardiac myocytes (2003) (0)
Bariatric surgery and inflammatory markers: the jury is still out: reply (2009) (0)
Abstract 14618: Fasting Glucose, NT-proBNP, Treatment With Glycoprotein IIb/IIIa Inhibitors, and Outcomes in Non-ST-Segment Elevation Acute Coronary Syndromes: An Analysis From EARLY ACS (2013) (0)
A Decrease in Plasminogen Activator Inhibitor-1 Activity after Successful PTCA is Associated with a Significantly Reduced Risk for Development of Coronary Restenosis (1991) (0)
THE ESTROGEN METABOLITE 17B-DIHYDROEQUILENIN COUNTERACTS INTERLEUKIN-1A INDUCED EXPRESSION OF INTERLEUKIN-6, INTERLEUKIN-8 AND MONOCYTE CHEMOATTRACTANT PROTEIN IN HUMAN ENDOTHELIAL CELLS IN VIT (2004) (0)
The ACVC transatlantic collaboration: an initiative for exchange of knowledge and science. (2021) (0)
6128A head-to-head comparison of uniform prasugrel treatment vs. clopidogrel treatment for confirmed responders in acute coronary syndrome patients: results from the randomized TROPICAL-ACS trial (2018) (0)
Prognostic relevance of TIMI flow and Nt-proBNP concentrations in ST-elevation myocardial infarction: a substudy of ASSENT IV-PCI (2008) (0)
Fibrinolytic, antiplatelet, and anticoagulant drugs in acute coronary syndromes (2021) (0)
3.P.72 Elevation of plasma lipid peroxidation products in patients with unstable coronary artery disease (1997) (0)
P580The influence of endurance races on copeptin and pregnancy plasma protein A (2018) (0)
European National Society Cardiovascular Journals. Background, rationale and mission statement of the "Editors' Club" (Task Force of the European Society of Cardiology). (2008) (0)
New insights into platelet function testing: From bench to bedside (2011) (0)
PP.26.19: EFFECTS OF RENAL DENERVATION ON BLOOD PRESSURE BURDEN IN AMBULATORY BLOOD PRESSURE MEASUREMENTS IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION IN A LONG TERM FOLLOW UP (2015) (0)
Blood group non-O is not associated with long-term adverse outcomes in patients undergoing percutaneous coronary intervention (2023) (0)
Basal and stimulated release of long-acting EDRF by bovine pulmonary arteries (1999) (0)
P789TLR-4 expression predicts mortality in patients with acute heart failure (2019) (0)
PROGNOSTIC CAPABILITY OF THE SYNTAX SCORE II AMONG 414 CONSECUTIVE PATIENTS WITH COMPLEX CORONARY ARTERY DISEASE WHO UNDERWENT CORONARY ARTERY BYPASS GRAFTING; PROUST STUDY (2018) (0)
TCT-217 Predictors of Dyspnea in Patients Receiving Ticagrelor After PCI: Insights From the Twilight Trial (2021) (0)
Fast Facts: Acute Coronary Syndromes (2014) (0)
activation of pro-survival kinases via EGF receptor transactivation The {delta}-opioid receptor agonist DADLE at reperfusion protects the heart through (2007) (0)
Regular Article Heme oxygenase-1 gene promoter polymorphism is associated with abdominal aortic aneurysm (2002) (0)
P 2 Y 12-receptor-inhibiting antiplatelet strategies in acute coronary syndromes (2017) (0)
SAFETY AND EFFICACY OF ADJUSTED-DOSE EPTIFIBATIDE IN PATIENTS WITH ACUTE CORONARY SYNDROMES AND REDUCED RENAL FUNCTION (2010) (0)
ID: 136 No Evidence for an Association of the Tissue-type Plasminogen Activator -7351C/T Enhancer Polymorphism and the Presence of Stable Coronary Artery Disease or the Occurrence of Acute Myocardial Infarction (2006) (0)
Abstract 4294: Migration of Intramyocardially Injected Porcine Mesenchymal Stem Cells in Remote Healthy Organs (2008) (0)
Contents Vol. 108, 2007 (2007) (0)
INHIBITION OF SMOOTH MUSCLE CELL MIGRATION BY EPTIFIBATIDE IN VITRO. EPTIFIBATIDE INHIBITS LOCALIZATION OF INTEGRIN αν-SUBUNIT TO FOCAL ADHESIONS (2004) (0)
Abstract 17235: Midregional Pro-A-Type Natriuretic Peptide as Part of a Dual Biomarker Strategy for the Early Rule Out of Non-ST Segment Myocardial Infarction - WilCop Study (2013) (0)
Contents Vol. 33 (2003) (0)
Is diversity harmful? - Mixed-brand cardiac implantable electronic devices undergoing magnetic resonance imaging (2021) (0)
Acute Cardiovascular Care 2019. (2019) (0)
Basic mechanisms in cardiogenic shock: part 2 - biomarkers and treatment options. (2022) (0)
GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide (2022) (0)
Association of Interleukin-32 and Interleukin-34 with Cardiovascular Disease and Short-Term Mortality in COVID-19 (2023) (0)
TCT-150 Prognostic Value of Different Definitions of Contrast Induced Acute Kidney Injury in STEMI: Analysis from the HORIZONS-AMI Trial (2012) (0)
mast cells and basophils C5a stimulates production of plasminogen activator inhibitor-1 in human (2013) (0)
Prognostic impact of active mechanical circulatory support in cardiogenic shock complicating acute myocardial infarction: results from the CULPRIT-SHOCK trial (2020) (0)
SEX DIFFERENCES IN PLASMA CONCENTRATIONS AND PROGNOSTIC VALUE OF NT-PROBNP IN CHRONIC HEART FAILURE (2019) (0)
ID: 069 The induction of matrix metalloproteinases by endotoxin in vivo is modulated by short term simvastatin-treatment (2006) (0)
Abstract 16576: The Role of Undetectable Cardiac High Sensitivity Troponin T and Copeptin for Prediction of 90 Day Outcomes in Low- to Intermediate-Risk Patients With Suspected ACS: A BIC-8 Biomarker Substudy (2014) (0)
Positionspapier der ÖDG und ÖKG Diabetes mellitus und Herzinsuffizienz // Chronic heart failure and diabetes. A position paper (2021) (0)
Atrial Fibrillation on Vitamin K Antagonist Undergoing Urgent Percutaneous Coronary Intervention for Non-ST-Elevation Acute Coronary Syndrome (2017) (0)
Chronic obstructive pulmonary disease in heart failure: influence on circulating biomarkers and outcome (2020) (0)
A matched case control study (2017) (0)
e n g l a n d j o u r n a l of m e d i c i n e PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock (2017) (0)
P2580Changes in extracellular vesicles during and after STEMI and potential influences of remote ischemic conditioning (2019) (0)
P3837Net clinical benefit of NOACs vs. VKAs in elderly patients with atrial fibrillation: a pooled analysis from the real-world PREFER in AF and PREFER in AF PROLONGATION registries (2018) (0)
Risk stratification and risk-adapted management of acute pulmonary embolism (2022) (0)
INTERLEUKIN-33 IS EXPRESSED IN HUMAN ATHEROSCLEROTIC TISSUE AND INCREASES PRO-INFLAMMATORY MEDIATORS IN HUMAN ENDOTHELIAL CELLS BUT NOT IN SMOOTH MUSCLE AND CARDIAC CELLS. (2010) (0)
Comparison and prognostic impact of electrocardiographic findings in COVID-19 pneumonia and non-COVID-19 pneumonia (2020) (0)
Psychotherapie in der Behandlung und Prävention des Tako-Tsubo-Syndroms: Empfehlungen für die klinische Praxis aus einer qualitativen Pilot-Studie // Psychotherapy in treatment of the Tako-Tsubo syndrome (2020) (0)
P485Monocyte subset distribution predicts survival in patients with acute heart failure (2018) (0)
Abstract 15905: Monocyte Subsets Predict Mortality After Cardiac Arrest (2020) (0)
P3447New frailty assessment based on routine nurse anamnesis before discharge is a strong predictor of all-cause mortality in patients with myocardial infarction (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Kurt Huber?

Kurt Huber is affiliated with the following schools:

University of Vienna
Medical University of Graz
Aarhus University
Medical University of Vienna
Uppsala University
Columbia University

Kurt Huber's Academic­Influence.com Rankings

Kurt Huber's Degrees

Why Is Kurt Huber Influential?

Kurt Huber's Published Works

Published Works

What Schools Are Affiliated With Kurt Huber?

Kurt Huber's AcademicInfluence.com Rankings